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Zusammenfassung 
Adoptiver Transfer Epstein-Barr Virus (EBV)-spezifischer, polyklonaler T-Zelllinien 
findet Anwendung bei Prophylaxe und Therapie Epstein-Barr Virus assoziierter 
Erkrankungen. Der Ansatz, obwohl prinzipiell effektiv, hat den Nachteil der sehr 
aufwändigen und diffizilen Herstellung der T-Zelllinien, welche aufgrund der Expansion 
unter Stimulation mit EBV transformierten B-Zelllinien oft nicht die gewünschten EBV 
Antigene erkennen. Vielmehr werden von solchen T-Zellen nur die immundominanten 
EBV Antigene erkannt. Eine Alternative zum polyklonalen T Zelltransfer stellt die 
Übertragung potenter, EBV-spezifischer T-Zellrezeptoren (TCRs) auf autologe T-Zellen 
dar. Dadurch können beispielsweise subdominante EBV Antigene angegangen werden, die 
von Tumorzellen tatsächlich exprimiert werden. 
In den hier beschriebenen Arbeiten, verwendeten wir Peptid beladene dendritische Zellen 
(DCs), um selektiv CD4+ T-Zellen gegen ein Epitop aus dem EBV Protein EBNA2 (EBNA 
= Epstein-Barr nuclear antigen) anzureichern. DCs sind hochpotente Antigen 
präsentierenden Zellen. Es gibt Hinweise darauf, dass sie sich besonders zur Stimulation 
von T-Zellen eignen, die subdominante EBV Antigene erkennen sollen. Mit Hilfe von 
RACE-PCR wurden die TCR Gene eines solchen CD4+ T-Zellklons, sowie zweier CD8+
Klone (Latent Membrane Protein (LMP) 2a- und EBNA3a-spezifisch), kloniert. Es wurden 
retrovirale Vektoren konstruiert, die die isolierten TCR Gene codieren. Mit ihnen sollte die 
EBV Spezifität der Klone auf andere T-Zellen (Linien und Primärzellen) übertragen 
werden. Die so modifizierten T-Zellen wurden dann auf ihre Funktionalität gegen EBV 
infizierte Zielzellen getestet. Wie bereits zuvor in anderen Laboren beobachtet, waren auch 
unsere TCR modifizierten T-Zellen zunächst nicht in der Lage, EBV infizierte Zielzellen 
effektiv zu attackieren. Erst durch Modifikation der Vektorstrategie (2A Peptidlinker aus 
Picorna Viren als Ersatz für das IRES (internal ribosomal entry site) Element) sowie der 
TCR Gene (Codon Optimierung) konnte eine deutlich verbesserte Expression und 
Funktion der modifizierten T-Zellen erreicht werden. Außerdem hing die Effektivität der 
modifizierten T-Zellen essentiell von der als Zielzelle verwendeten LCL ab. 
Die hier beschriebenen Arbeiten zeigen die erfolgreiche Übertragung von TCRs gegen 
EBV Antigene auf T-Zellen. Die so modifizierten T-Zellen erlangten anti-EBV Aktivität 
und sprechen daher für die prinzipielle Anwendbarkeit TCR-modifizierter T-Zellen zur 
Behandlung EBV assoziierter Erkrankungen. 
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Summary 
Adoptive transfer of polyclonal Epstein-Barr-virus (EBV)-specific T cell lines has been 
used as prophylaxis and therapy in patients with EBV-associated malignancies. This 
approach, however, is limited by the time-consuming and unspecific expansion of 
polyclonal T cells directed mainly against the dominant EBV antigens presented on EBV-
transformed B cell lines. Isolating high-affinity, EBV-antigen-specific T cell receptors 
(TCRs) for transduction of T cells is an alternative strategy to confer T cell immunity 
against EBV antigens including subdominant EBV antigens. 
In this study, we have used peptide-pulsed DCs to selectively expand EBV-specific CD4+
T cell clones against an epitope derived from the EBV protein Epstein-Barr nuclear antigen 
(EBNA)2. DCs are highly potent antigen-presenting cells and data suggested that peptide-
pulsed DCs are particularly effective in generation of T cell lines specific for subdominant 
EBV antigens. TCR genetic information from one of these clones as well as from two 
CD8+ T cell clones specific for epitopes from EBNA3a and latent membrane protein 
(LMP) 2a was identified by RACE PCR. TCR alpha and beta chains where then cloned 
into retroviral vectors for transduction of T cell lines and primary T cells to equip them 
with anti-EBV specificity. The TCR-modified T cells where then tested for their newly 
acquired specific function towards EBV-positive target cells to assess the chances for the 
use of EBV-redirected T cells in adoptive immunotherapy of EBV-associated disease. Like 
in previous studies by other groups, our EBV-specific TCRs at first did not confer effective 
activity against EBV-positive LCLs. Instead, we had to apply modifications to the TCR 
vectors in order to improve expression and function of the introduced TCRs. Codon 
optimization as well as replacement of the IRES site by a 2A peptide linker was required to 
significantly increase expression and function of transduced TCRs in primary T cells. Also, 
we found that the effectiveness of TCR transduced T cells is dependent on the target LCLs 
chosen. 
Our data show successful transfer of functionally active EBV-specific TCRs into T cells to 
render them effective against EBV-positive LCLs, representing the basis for the 
development of TCR-transgenic T cells for adoptive T cell transfer in EBV-associated 
malignancies.
Introduction 1.1 Tumor Immunology
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1 Introduction  
1.1 Tumor Immunology 
1.1.1 Tumor Immunosurveillance 
The beginning of modern tumor immunology dates back to the 1950s when, for the first 
time, tumor-specific rejection of implanted tumor tissue was demonstrated in animals [1]. 
In 1970 the tumor immunosurveillance hypothesis was formulated [2]. It suggests that 
tumors are eliminated by the immune system upon recognition of tumor antigens that are 
expressed by tumor cells during malignant transformation and proliferation. In fact, 
patients whose immune system is impaired by disease, e.g. HIV infection or by post-
transplantation immunosuppression, more frequently suffer from malignant disease [3]. 
The cancers that develop in such patients due to the lack of sufficient immune control, 
mainly arise from virus-associated tumors in which peptides derived from viral proteins are 
presented as neoantigens. This reflects the inability of the immune system to efficiently 
fight off the infectious agents rather than a general inability to control cancer development 
and growth. Although these immune reactions are actually directed towards the virus 
instead of the tumor itself, the existence of anti-tumor reactions, e.g. in melanoma patients, 
and the roles that T cells play in these reactions are well-documented. 
1.1.2 Tumor Antigens 
Tumor-specific antigens (TSA) which are solely expressed on tumor cells and not on any 
normal cells are rare and must be discriminated from tumor-associated antigens (TAA). 
TAA can result from abnormally high expression of genes that lead to expression of 
otherwise non-presented or at very low frequency presented antigens. In a normal 
individual, the expression of these genes can be restricted to certain tissue types (i.e. HER-
2/neu in mammary cancer [4]) or stages of development (i.e. MAGE-1 and MAGE-2 
antigens in melanoma [5]). Examples for TSAs are BCR/ABL fusion proteins as well as 
peptides derived thereof (e.g. in chronic myeloid leukaemia = CML), frame-shift mutation-
derived peptides (e.g. in colorectal cancer) or peptides from viral oncogenes (e.g. in 
Papilloma virus, Cytomegalo virus, Epstein-Barr virus). In theory, TSAs are best-suited as 
targets for immune intervention as a treatment of cancer. As a completely foreign structure 
Introduction 1.1 Tumor Immunology
8
they would trigger the most potent immune response, at the same time reducing the risk of 
autoimmunity. However, it is extremely difficult to find a good target for anti-cancer 
immunotherapy: TSAs are rare and e.g. in the case of BCR/ABL in CML, fusion peptide-
specific T cells are indeed detectable, but obviously incapable of preventing malignant 
progression in the patient. Most antigens that are being considered for immunotherapy of 
cancer are TAAs. These antigens bear a higher risk of autoimmunity or low T cell avidity. 
Many tumor-associated antigens are self antigens. T cells recognizing these TAA with high 
affinity are consequently deleted in the thymus as demanded by the mechanism of central 
tolerance. By contrast, potent T cells specifically targeting foreign antigens such as viral 
epitopes are present. As true non-self antigens, virus-derived epitopes are very attractive 
targets when viral infection drives malignant transformation. In the case of EBV, clinical 
data showcase the effectiveness of the immune system to control EBV-driven tumor 
progression in healthy individuals (see chapter 1.3.1). However, viruses have mostly 
evolved to the ability to avoid detection by the host immune system and can therefore 
escape complete elimination. 
1.1.3 Antigen Processing and Presentation  
1.1.3.1 HLA Class I Pathway 
In general, peptides presented in HLA class I context stem from intracytosolic or nuclear 
proteins. These peptides can be derived from tumor-associated or viral antigens. After 
proteasomal degradation and TAP-catalyzed (TAP = transporter associated with antigen 
processing) translocation of peptides into the endoplasmic reticulum HLA:peptide 
complexes comprising HLA heavy and light chain as well as the peptide epitope are 
assembled. Subsequent vesicular transport provides HLA:peptide complexes ready for 
T cell recognition at the cell surface. HLA class I-presented epitopes are usually 
recognized by CD8+ which can then kill the target cell. 
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1.1.3.2 HLA Class II Pathway 
As opposed to HLA class I molecules which are expressed on all nucleated cells, class II 
molecules are exclusively expressed by professional APC such as DC or activated forms of 
macrophages and B cells. The conventional way of class II-restricted antigen presentation 
describes a mechanism to process and display antigenic structures that originate from the 
extracellular space and present them to CD4+ T cells. Prior to their presentation to T cells, 
such antigens are phagocytosed into the APC and degraded in lysosomal compartments. 
However, HLA class II-restricted presentation of endogenous antigens has been described 
which bypass conventional pathways [6,7,8]. Therefore, it is also possible for intracellular 
antigens such as viral epitopes to be presented to CD4+ cells. The importance of those 
CD4+ T cells’ contribution to anti-tumor immunity is unquestioned. The mechanisms and 
interactions, however, remain unresolved. 
1.1.3.3 Dendritic Cells as APCs  
Dendritic cells are highly potent APCs [9,10,11,12,13,14]. Whilst stimulating T cells with 
EBV-transformed LCLs favors the growth of T cells targeting dominant EBV epitopes, 
using peptide-pulsed DCs as APC is a more efficient tool to specifically expand T cells 
that target selected subdominant EBV antigens [15,16]. The method is effective for 
isolation of T cells specific for either class I- and class II-restricted epitopes. To apply this 
method, however, the precise peptide sequence of an epitope must be known. 
1.1.4 Role of CD4+ T cells 
During the last years, our understanding of the role of CD4+ T cells has undergone 
elementary changes. Today, the focus no longer lies merely on the function of CD4+
T cells as helper cells. Much more attention is paid to the suppressor and regulatory 
functions of CD4+ T cells. Furthermore, antigen-specific and HLA-restricted cytolytic 
function of CD4+ T cells has been reported in numerous studies [17,18] (for review see 
[19,20]). As reported in these studies, mostly viral epitopes (e.g. HIV) are found to be 
detected by such CD4+ CTL. However, the studies of CD4+ CTL have long been criticized 
as being mainly restricted to cell lines and in-vitro-generated T cell clones, thus being 
irrelevant in-vivo. That was before cytotoxic CD4+ T cells in HIV and CMV patients 
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[21,22] as well as other non-viral diseases could be detected directly from peripheral blood 
without prior in-vitro stimulation. Numerous reports argue against the idea of cytotoxic 
CD4 cells just being in-vitro artefacts. In-vitro-generated human CD4+ CTLs have been 
described for CMV, EBV BKV, vaccinia, HIV, mycobacteria and Cryptococcus 
neoformans. TAP-dependent ways for presentation of intracellular epitopes in an MHC 
class II context have been described [7,8] providing explanation on how intracellular virus- 
or tumor-derived antigens might be processed and presented. We believe that CD4+ T cells 
should be considered for application in immunotherapeutic approaches. Next to the help 
they can provide to generate and maintain cytotoxic function of CD8+ T cells, cytotoxic 
CD4+ T cells might also add to the arsenal of anti-tumor T cells that kill antigen-bearing 
cells. A study utilizing CD4+ and CD8+ EBV-specific T cells to treat EBV-associated HD 
and nasopharyngeal carcinoma has been conducted with promising results [23]. CD4+
cytotoxic T cells are believed to play a key role in LCL outgrowth control [24].
Introduction 1.2 T cell receptors
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1.2 T cell receptors (TCR) 
1.2.1 Antigen Recognition by T cells 
Recognition of MHC-bound antigenic peptides via TCRs is required for a functional T cell 
response. APCs present peptide epitopes complexed with surface MHC molecules. These 
peptides result from cytoplasmic protein degradation and are required for detection by 
CD8+ T cells. By contrast, MHC class-II-bound peptides usually originate from proteins 
that were taken up by the APC by endocytosis. Exceptions to the rule are evident and 
awareness thereof is crucial for the understanding of the strategy chosen in some of the 
experiments described in this work. While MHC class I molecules are present on all cells, 
class II molecules are only expressed by professional APCs (B lymphocytes, DCs, 
macrophages). Antigen recognition occurs with ligation of the TCR and its coreceptor 
(CD4 or CD8 respectively) to the MHC:peptide complex (figure 1). For activation of the 
T cell additional costimulatory signals have to be provided by the same APC. Such 
costimulation can be given by binding of CD28 on the T cell with a B7 molecule on the 
APC. The vast majority of T cells from peripheral blood are alpha:beta T cells with TCRs 
consisting of one alpha and one beta chain. A very small population of T cells has TCRs 
made up of one gamma and one delta chain and are therefore referred to as gamma:delta 
T cells whose biological function is still under debate (for review see [25]). Only 
alpha:beta T cells and their TCRs shall be discussed hereafter. Figure 1 shows a simplified 
model of the binding of HLA:peptide complexes by TCRs of CD4+ and CD8+ T cells. 
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CD4+ T CELL CD8+ T CELL
APC APC
TCR
peptide antigen
HLA class IICD4 HLA class I
peptide antigen
TCR
CD8
Fig. 1: TCR-mediated antigen recognition by T cells. T cells recognize antigenic peptides on the 
surface of APCs in context of HLA molecules. CD4+ T cells target HLA class II complexes 
whereas CD8+ T cells target HLA class I complexes. The CD4 and CD8 coreceptors are shown. 
They bind to the HLA molecules to increase avidity and to allow proper activation of the T cell 
after antigen is bound via its TCR. (based on illustrations shown in “Janeway’s immunobiology” 
[26])
1.2.2 TCR genetics 
TCRs are membrane-bound molecules composed of one alpha and one beta polypeptide 
chain that are linked by one disulfide bond. By association of a TCR with CD3 the T cell 
receptor complex is formed. The human TCR locus is mapped to chromosomes 7 (beta 
chain locus) and 14 (alpha chain locus). Each TCR alpha chain is made up of a 
combination of variable (V), joining (J) and constant (C) segments. As opposed to alpha 
chains that have only one C-region, beta chains have two C-regions (C1 and C2) and also 
an additional diversity (D) segment. Somatic recombination events in developing 
T lymphocytes as well as splicing at the mRNA level result in the random association of 
V(D)J blocks that comprise the V-region. Taking thymic selection and non-functional 
TCRs into account, this leads to an estimated number of 109 TCR specificities per 
individual [27]. A simplified scheme (based on [26]) of TCR gene rearrangement is shown 
in figure 2. Each TCR has one antigen-binding site, the complementarity-determining 
region (CDR) 3, while CDR 1 and CDR 2 bind to HLA in a non-antigen-specific manner. 
The CDR3 loop lies directly at the interface between TCR and peptide:HLA complex 
making direct contact with the antigenic peptide. 
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L Vα x 70-80 Jα x 61 Cα
α-chain locus
Cβ1 Dβ2L Vβ x 52 Jβ1 x 6Dβ1 Cβ2Jβ2 x 7
β-chain locus
TCR
α-chain
β-chain
Vα
Jα
Cα
Vβ
Dβ Jβ
Cβ
Fig. 2: TCR gene rearrangement. Recombination of a variable (V), joining (J), diversity (D) 
(beta chain only) and constant (C) region gives rise to the diversity of TCR specificity. The 
numbers indicate the number of segments for each locus. Due to somatic recombination and 
splicing at the mRNA level, each individual will has an estimated repertoire of 109 different TCR 
specificities with each TCR comprising one V, one J (one D in beta chain) and one C segment. 
Each TCR chain contains a V-specific leader sequence (L). 
1.2.3 Adoptive T cell Therapy with Allogeneic and TCR-modified T cells 
Adoptive immunotherapy has been successfully used to treat cancer (for reviews see 
[28,29,30]). Its strong potential has been first reported in 1990 by Kolb et al. after the 
treatment of chronic myeloid leukaemia patients using donor leukocyte infusion (DLI) 
[31]. In that study, they demonstrated the effect of therapeutic DLI in patients with 
recurrent CML. In patients suffering from post-transplantation lymphoproliferative disease 
(PTLD), adoptive transfer of EBV-specific polyclonal CTL lines has also shown some 
respectable success [32,33,34]. However, this approach is hampered by the difficult 
isolation and expansion of EBV-specific T cells due to their very low frequency. 
In the late 1990s early publications described the transfer of TCR genes into T cell lines 
[35] and primary T cells [36] in order to transfer antigen specificity. Transducing TCR 
alpha and beta chain genes into activated T cells is an alternative option to generate large 
numbers of antigen-specific T cells. Within a few weeks, autologous T cells can be 
equipped with suitable TCR specificity, expanded and given back to the patient. Basically, 
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antigen specificity from characterized T cells can be transferred to T cells of any patient 
with compatible HLA alleles. This approach comprises the identification and isolation of 
TCRs from defined T cell clones followed by transduction of activated T cells. The 
redirected T cell specificity can be generated within several days and the practicability of 
this strategy has been shown (for review see [37,38,39]). TCR transduction of patient 
peripheral blood lymphocytes (PBLs), as performed for the first time by Clay et al., has 
been shown to convey antigen-specific function ex-vivo [36]. In-vivo, mouse models have 
demonstrated that adoptively transferred TCR-transgenic T cells are functionally active 
and efficiently home to effector sites [40,41]. Also, antigen-specific expansion of TCR-
redirected T cells and clearance of a viral infection was shown by Kessels et al. [40]. Using 
non-obese diabetic severe combined immunodeficiency (NOD/SCID) mice as a model, 
Xue et al. demonstrated the elimination of human leukemia cells by TCR-transgenic 
human T cells targeting a leukemia-specific antigen [41]. 
A clinical phase I trial using TCR-redirected T cells has indicated the feasibility and safety 
of utilizing TCR-gene-modified T cells for adoptive therapy [42]. A melanoma-reactive 
TCR (MART-1) was used to redirect the specificity of PBLs which were subsequently 
transferred into patients. This study showed an objective response in 2 out of 17 patients 
[42]. The TCR used in this study had been isolated from a tumor-infiltrating lymphocyte 
(TIL) clone from a patient who had been successfully treated with adoptively transferred 
autologous melanoma-specific T cells [43]. Recently, a second study showed undesired 
side effects due to administration of TCR-modified T cells to patients ([44] see discussion). 
1.2.4 T cell receptor Optimizations 
The field of TCR gene transfer has been struggling with problems such as low transgene 
expression and low antigen-specific efficacy. It has also been shown that some TCRs are 
dominant over others when competing for surface expression [45]. Based on that finding, 
the concept of relatively “weak” and “strong” TCRs was introduced. Furthermore, 
concerns about undesired effects were frequently stated; unpredictable risk factors are the 
formation of mixed TCR hybrids by pairing of introduced TCR chains with endogenous 
chains as well as off-target toxicity by the endogenous TCR due to activation of the 
introduced TCR. In theory, these scenarios can lead to autoimmune pathology. 
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Reports about EBV-targeted TCR gene transfer have suffered from very low expression 
rates leading to weak antigen-specific responses [46,47]. In these studies, the use of 
nucleofection and retroviral transduction to redirect donor PBLs to EBV antigens has only 
led to very low expression levels of less than 2% [46]. It seems as if EBV-specific TCRs 
tend to be rather “weak” and, when unmodified, fail to achieve a sufficiently high surface 
expression. 
We wanted to overcome the problems of low expression rates by TCR engineering. In this 
work, we describe two optimization measures that aim at increasing the efficacy of TCR 
transfer and surface expression in the recipient cell; to turn a “weaker” TCR into a 
“stronger” one. The optimizations utilized in this work comprise codon optimization and 
introduction of a 2A linker as a replacement for the IRES site. Codon optimization has first 
been reported to be effective in improving TCR expression by Scholten et al. [48] and, 
since then, has been confirmed to benefit TCR expression in many cases. In the process of 
codon optimization best codons are chosen with regard to the availability of the 
corresponding tRNA. At the same time rare codons, as well as RNA instability motifs and 
undesired splice sites etc. are eliminated from the nucleic acid sequence. By increasing 
desired TCR gene expression, competition is skewed in favor of the introduced TCR. 
Replacing the IRES site with the much smaller 2A linker [49] is another way of increasing 
TCR expression as a result of improved efficiency in transfection and transduction. 
Furthermore, the integration of the 2A linker, in theory, allows for equimolar expression of 
both introduced TCR chains; alpha and beta chain genes can be translated by the same 
ribosome which receives a skip signal by the linker, thus releasing the beta chain before 
translating the downstream alpha gene. In our experiments, the modifications consistently 
led to higher numbers of T cells which expressed the introduced TCR as well as higher 
mean fluorescence values when directly compared to the vectors with non-optimized 
sequences and an IRES site. Both optimization measures applied in this work are restricted 
to the nucleic acid level and leave the original amino acid sequences of the TCRs 
untouched. 
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1.3 Epstein-Barr Virus (EBV) 
Primary infection with EBV can but need not lead to a clinical situation termed infectious 
mononucleosis (IM), an illness characterized by lymphoadenopathy as well as spleen and 
liver enlargement. Either way, once infected the host carries the virus for life. EBV 
infections demonstrate the power of the human immune system which prevents the 
outgrowth of virus-infected cells. It is only in the immunosuppressed host that this 
immunosurveillance fails. Figure 3 shows an overview of the EBV genome (figure and 
legend from review [50]). The Diagram shows the location and transcription of the EBV 
latent genes on the double-stranded viral DNA episome. The latent proteins include the six 
nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and the three latent 
membrane proteins (LMPs 1, 2A and 2B). EBNA-LP is transcribed from a variable 
number of repetitive exons. LMP2A and LMP2B are composed of multiple exons, which 
are located on either side of the terminal repeat (TR) region, which is formed during the 
circularization of the linear DNA to produce the viral episome. Transcripts from the 
BamHIA region can be detected during latent infection, but no protein arising from this 
region has been definitively identified. 
Fig.. 3: The Epstein–Barr virus genome. The large green solid arrows represent exons encoding 
each of the latent proteins, and the arrows indicate the direction in which each gene is transcribed. 
The blue arrows represent the highly transcribed non-polyadenylated RNAs EBER1 and EBER2; 
their transcription is a consistent feature of latent EBV infection. The long green arrow represents 
EBV transcription during latency III (Lat III), in which all EBNA genes are transcribed from either 
the Cp or Wp promoter.The different EBNAs are encoded by individual mRNAs that are generated 
by differential splicing of the same long primary transcript. The red arrow represents the EBNA1 
transcript, which originates from the Qp promoter during Lat I and Lat II. 
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1.3.1 EBV Infection in Immunocompetent Hosts 
Over 90 % of the adult human population are latently infected with EBV [51]. EBV, a 
gamma herpes virus, targets long-lived B lymphocytes, which promotes the virus’ 
persistence in the host. The oncogenic potential of EBV is a result of its transforming 
capacity in B lymphocytes. Primary EBV infections initiate humoral and cellular immune 
responses that lead to immunologic control, but not elimination of the virus. In the 
infectious life cycle six nuclear antigens (EBNA1, 2, 3A, 3B, 3C and EBNA LP) as well as 
three latent membrane proteins (LMP1, 2A and 2B) are expressed. Other genes (EBER1 
and 2) are not yet completely characterized [50]. EBNA1, 2, 3A, 3C and LMP1 contribute 
to the transformation of B lymphocytes to lymphoblastoid cell lines (LCLs) with unlimited 
proliferative capacity [50,51]. Infected cells exhibit lytic viral proliferation and circulate in 
the host until controlled by the host immune system. The majority of infected individuals 
remain asymptomatic. However, delayed primary infection during or after adolescence can 
lead to IM. The incubation time is approximately 30 days before IM patients exhibit 
symptoms such as fever, sore throat, pain and drowsiness. High infectious virus titers are 
then shed in the patients’ throats due to lytic infection of orapharyngeal sites. 
Simultaneously, lytically infected B cells accumulate in the tonsils. Although in-vitro both 
naïve and memory B cells are susceptible to EBV infection, EBV-infected cells are 
concentrated in the IgD-CD27+ memory phenotype B cell subset [52,53]. In long-term 
virus carriers these cells have returned to a resting state with most viral proteins down-
regulated [54]. Primary EBV infections elicit potent cellular immune responses that 
ultimately control the virus. Lymphocytosis during IM reflects expansion of CD8+ T cells. 
These T cells that target both lytic- and latent-cycle antigens are later maintained in the 
CD8 T cell memory repertoire at combined levels up to 5 % of total CD8+ cells [55]. 
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1.3.2 EBV Protein Expression in Latent Infection 
According to the arrays of EBV-encoded proteins expressed, different latency stages of 
EBV-infected cells are defined (see also tab. 1). 
Type I latency 
In type I latency only EBNA1 is expressed. The phenotype corresponds to non-activated 
B cells and does not promote proliferation. EBNA1-derived epitopes are not available for 
T cell recognition because its long glycine-alanine repeats protect it from proteasomal 
degradation and resultingly from HLA class-I-restricted presentation. Type I cells are 
found in healthy individuals. In this state EBV can persist by securing the maintenance of 
virus-carrying cells as well as by not attacking the host. 
Type IIa latency 
Here, the EBV gene expression is restricted to EBNA1 as well as LMP1 and 2. This 
program is found in non-B cells including malignant cells from nasopharyngeal carcinoma 
and EBV+ Hodgkin-, T- and NK-cell lymphomas. Cell proliferation is not induced due to 
the lack of EBNA2 expression which is crucial for inducing proliferation of EBV-infected 
B cells. 
Type IIb latency 
Cells in type IIb stage express all EBNA proteins. With the lack of LMP1 expression, type 
IIb as well as type IIa cells (no EBNA2) are characterized by the absence of one protein 
crucially required for transformation. Type IIb cells have been observed in B-CLL cells as 
well as lymphoid tissues of IM patients and in PTLD. 
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Type III latency 
The so-called growth program, as named by Thorley-Lawson, is also referred to as type III 
latency and is expressed only in B cells. Here, the full set of EBV-encoded proteins is 
expressed. The products are translated into six nuclear proteins (EBNA1 – 6) and three 
membrane proteins (LMP1, 2a and 2b). By complex virus-cell and cell-host interactions, 
they activate cellular genes. Cells expressing the type III program are highly immunogenic 
and can therefore only exist in the acute phase of a primary infection before anti-EBV 
immunity is manifested or in immunocompromised patients which can then lead to PTLD. 
Tab. 1: Gene expression programs for EBV latent infection [56,57] 
Latency type Protein expresseion Function Disease 
I EBNA1, LMP2a Allows persistence of the 
virus in resting recirculating 
memory cells in a way that is 
non-pathogenic and not 
detectable by the immune 
system 
BL 
II EBNA1, LMP1/2a/2b Provides necessary survival 
signals for: 
(i) infected lymphoblasts to 
differentiate into memory, 
and 
(ii) maintenance of 
persistently infected memory 
cells 
NPC 
HD 
III EBNA1/2/3A/3B/3C, 
LMP2a/2b 
Activates a resting B cell to 
become a proliferating 
lymphoblast 
PTLD, IM 
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1.3.3 EBV-associated Malignancies 
Although virtually all adults are infected, they can remain asymptomatic for life due to 
efficient immune control. Only a few cells harbouring EBV are found in lymphoid tissue 
and in a very small population of circulating B cells (0.1 – 24 latently infected B cells per 
million PBMCs) [58]. However, equilibrium of immune control and EBV replication and 
latency can be skewed when the immune system is compromised. The immune system can 
be impaired by mechanisms such as immunosupressive therapy after transplantation or by 
infection with HIV. Ineffective anti-virus CTL activity can then lead to enforced viral 
replication in the oropharyngeal space as well as to elevated numbers of infected B cells. 
The transforming capacity is encoded in six nuclear and three membrane proteins. The 
expression of EBV proteins depends on the cell type as well as its differentiation and 
activation status. Several malignant diseases have been linked to EBV infection. 
1.3.3.1 Burkitt’s Lymphoma (BL) 
BLs are subcategorized into endemic, sporadic and AIDS-associated types. EBV is mainly 
found in the endemic type of the disease [59] and increased EBV antibody titers coincide 
with a higher incidence of BL [60]. In the endemic and AIDS-associated BL types, EBV 
association varies strongly between ~ 20 % and ~ 70 % [61,62]. BLs exhibit a 
characteristic chromosomal translocation of the c-myc gene from chromosome 8 to 
chromosome 14, seldomly to chromosomes 2 or 22 into close proximity of the human 
immunoglobulin genes [63]. Chromosomal translocations leading to constitutive c-Myc 
activation result in the induction of B cell proliferation. Immunosurveillance against EBV 
fails in the case of BLs, because EBV is expressing the latency I program, downregulating 
all viral genes except EBNA1 [64]. Additionally, antigen presentation is impaired due to 
downregulation of TAP1/TAP2 (transporter associated with antigen processing) genes 
[65]. As a result, BL is probably unsuitable for immunotherapeutic intervention. However, 
administration of IFN-gamma has improved antigen processing in BL cell lines [65]. Also, 
EBNA1-specific CD4+ T cells could be induced in a BL mouse model [66].
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1.3.3.2 Morbus Hodgkin (Hodgkin’s disease = HD) 
The hallmarks of Hodgkin’s tumors are the mononuclear Hodgkin cells as well as the 
multinuclear Reed-Steinberg cells (RS cells), that together make up about 1-2 % of the 
total tumor mass. It is now assumed that Hodgkin cells originate from crippling mutated 
germinal center B cells. 40-60 % of Hodgkin-Reed-Steinberg-cells (HRSC) are positively 
tested for the presence of EBV DNA [67] and express the latency II program. A role for 
EBV, however, can be observed in analyzing epidemiologic data. The average age of 
primary EBV infection coincides with the age-correlated incidence of HD. Moreover, the 
risk of developing HD is increased by threefold in individuals who have a history of 
infectious mononucleosis [68]. As opposed to BL, HD cells do not seem to be impaired in 
their antigen processing machinery [69]. Although the immune system apparently fails at 
controlling EBV+ HRSCs, LMP2a-specific T cells from HD patients could be expanded 
ex-vivo and where transferred to patients with refractory or relapsing disease with partial 
success [70,71]. The reason for the insufficiency of T cell control might be due to a weak 
LMP2-specific T cell response or cytokine-induced T cell suppression. Therefore, the 
transfer of activated LMP1- and LMP2-specific T cells or TCR-modified T cells remains a 
therapeutic option. 
1.3.3.3 Nasopharyngeal Carcinoma (NPC) 
NPC is a malignant neoplasm which is more frequent in Asia and northern Africa and 
which arises from the mucosal epithelium of the nasopharynx. The most common form of 
NPC is the undifferentiated non-keratinized type, in which most transformed epithelial 
cells carry monoclonal EBV-DNA [72]. In NPC EBV seems to infect epithelial cells prior 
to malignant transformation whereas in healthy individuals no EBV-DNA can be detected 
in biopsies of the epithelium [73,74]. As in HD, the latency II program of EBV is 
expressed. Again, the immune system is incapable of controlling the disease. Nonetheless, 
EBV-specific T cells could be detected in NPC biopsies giving hope to immunotherapeutic 
approaches [75]. Two studies have applied adoptive transfer of EBV-specific T cells to 
treat NPC with some success [76,77]. Also, using peptide-pulsed DCs as vaccines, LMP2a-
specific T cell counts could be increased in 75 % of NPC patients [78]. 
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Post-Transplantation Lymphoproliferative Disorders (PTLD) 
Immunosuppression after organ transplantation can favor the outgrowth of PTLD 
lymphomas, mostly during the first year after transplantation when immunosuppression is 
most severe. Almost all of these tumors are EBV-positive and express the latency III 
program that, under normal conditions, would be controlled by T cell surveillance. Some 
of the lymphomas that arise in AIDS patients with strongly impaired immune systems have 
the same phenotype. The incidence as well as time of diagnosis of PTLD tumors varies and 
depends on the type of transplanted organ [79]. An infection with EBV is crucially 
contributing to most early PTLDs. Immunosuppression shifts the equilibrium of EBV-
infected B cells and EBV-controlling T cells leading to accumulation and outgrowth of 
infected B cells [80]. Cancerous EBV-induced B cell proliferation in PTLD showcases the 
latency III expression pattern of viral proteins. They are functional as APC expressing 
MHC class I and II molecules as well as costimulatory molecules. Lowering the dose of 
immunosuppression has led to remission [81] proving the potential immunogenicity of 
PTLD cells. Adoptive transfer of polyclonal EBV-specific cytotoxic T cell lines has been 
successfully applied in the treatment of PTLD patients [82,83]. 
1.3.4 Pharmacological Therapy 
Conventional treatment encompasses a combination of surgery, radiotherapy and 
chemotherapy. In the case of PTLD, a reduction of immunosuppression can also lead to a 
reduction of lymphoproliferation [81]. Additionally, various pharmacotherapeutic 
approaches have been developed and tested for their suitability to treat EBV-associated 
disease (for review see [50]). For example, the lytic cycle of EBV has been induced (by 
administration of agents such as arginine butyrate) to render infected cells susceptible to 
antiviral treatment with ganciclovir [84,85,86]. Other antiviral drugs (e.g. foscarnet, 
cidofovir) are available for use.
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1.3.5  Immunotherapy 
1.3.5.1 Monoclonal Antibodies 
Anti-CD20 monoclonal antibodies are a potent mode of immunotherapeutic intervention 
against B cell lymphomas like EBV-associated PTLD [87]. These antibodies mediate 
antibody- and complement-dependent cytotoxicity (ADCC, CDC) as well as 
antiproliferative effects against B cells. In a German phase II clinical study on the efficacy 
of Rituximab monotherapy, complete remission was achieved in 9 out of 17 patients [88]. 
Other studies, as well, had positive results [89,90,91]. The loss of normal B cells that are 
cleared by the antibody alongside tumor cells does not have a fatal inpact on serum Ig 
levels in patients [91]. However, frequent resistance to Rituximab treatment is evident (e.g. 
in relapses after prior response to treatment [92]) and encompasses diverse yet not fully 
understood causes [93,94]. 
1.3.5.2 Adoptive Polyclonal T cell Therapy 
Several studies using polyclonal autologous CTL lines to treat PTLD patients have been 
conducted with some success [83,95]. These CTL lines had been generated using EBV-
transformed LCLs as APC and therefore suffer from several drawbacks: LCL-stimulated 
T cells primarily recognize immunodominant EBV epitopes such as EBNA3a, whereas 
some EBV-associated malignancies, such as HD or NPC, only express subdominant 
antigens such as LMP1/2 or EBNA1 [16]. Furthermore, the approach is hampered by the 
time-consuming, expensive and difficult generation of EBV-reactive CTL lines for each 
individual patient. As a result, adoptive polyclonal T cell therapy has predominantly been 
used as prophylaxis in high-risk patients [34,96,97]. However, the recent use of a CTL 
bank for administration of partially matched allogeneic CTL has also demonstrated some 
significant activity [33]. 
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1.3.5.3 Adoptive Therapy with TCR-modified T cells 
While in the majority of reports, redirected T cells were endowed with TCRs recognizing 
tumor-associated antigens, only a few studies described the genetic modification with 
TCRs targeting viral antigens. TCRs specific for the human immunodeficiency virus I Gag 
and Pol antigens [61,98] and hepatitis C virus NS3 antigen [99] have been isolated and 
transferred. Also, TCRs specific for viral antigens associated with human cancer such as 
human papilloma virus 16E7 [48] and EBV (EBNA3a, 3b, LMP2) [46,47,100] have been 
used to confer T cell specificity. However, reports that described the generation of EBV 
antigen-specific T cells by TCR gene transfer bore several problems: firstly, the retrovirus 
vector encoded, in addition to the TCR genes, a selectable marker gene (e.g. neomycin) 
which is very immunogenic and may lead to immune responses against the TCR-redirected 
and G418-selected T cells [101]. More importantly, due to poor transduction efficiency and 
expression of the transgenic TCR the antigen recognition was weak on target cells [46]. 
Lastly, the transgenic TCR had to be modified, e.g. by the introduction of a CD28 domain 
to overcome the non-responsiveness towards the target antigen [100]. So far, applicability 
of EBV-specific TCRs is limited due to poor expression and antigen sensitivity, thus 
making their application difficult. 
1.4 Outline of this Thesis 
The aim of this thesis was to re-evaluate the potential of TCR-modified T cells to target 
EBV antigens. Although some groups have been trying to elucidate the chances of such an 
approach, previous efforts faced several problems that were yet to be overcome. These 
problems basically condensed into one major issue: insufficient surface expression of the 
introduced TCR and, as a result, low efficacy towards antigen-bearing target cells. We set 
out to tackle these problems with three different approaches: 
First, we wanted to start out choosing the right clones that showed good antigen-specific 
activity after using peptide-pulsed DCs as stimulators. 
Introduction 1.4 Outline of thesis
25
Second, we sought to optimize surface TCR expression by modifying the vector as well as 
the TCR chains themselves using genetic engineering tools. 
Third, we would assess the role of the chosen target LCLs in the attempt to show a 
convincing antigen-specific activity of TCR-modified T cells. 
Adoptive T cell therapy has been successfully applied to treat EBV-associated disease. 
Despite this fact, many patients can still not be cured, because adoptive transfer of 
polyclonal CTL is not always an available option. Limitations of the technology are the 
time and effort required to establish autologous CTL for each patient. TCR transfer is 
being developed for improved applicability in patients in the treatment of various diseases. 
TCR-modified T cells are an alternative strategy of adoptive therapy. In the future, they 
might avoid laborious generation of autologous CTL by reliably making TCR-modified 
CTL available in much shorter time. TCRs that target EBV have been described in the 
literature, but have not yet resulted in clinical testing. That is because the TCRs that had 
been isolated from EBV-specific T cell clones were ineffective once transferred into 
recipient T cells, rendering the TCR-modified useless in combating EBV-infected cells. 
TCR expression in the said publications was poor and so was the quality of the T cell 
response of redirected T cells towards antigen-bearing cells. The aim of this research was 
to isolate suitable EBV-specific T cells using peptide-pulsed DCs to then identify the 
corresponding TCRs by molecular cloning. Trying to overcome the problems researchers 
had faced in the past, I would be utilizing state-of-the-art technology to improve TCR 
expression and function to create more effective EBV-specific T cells. 
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2 Material and Methods 
2.1 Consumables and Instruments 
Consumables Manufacturer
2-log DNA ladder New England Biolabs, USA
AB serum, human Lonza, Switzerland 
Antibodies for flow cytometry (general) BD Biosciences, Germany 
(Vbeta panel antibodies) Beckman-Coulter (Immunotech), USA 
BrightGlo Promega, USA 
Monoclonal antibodies (mAb) 
 Anti-human CD3 mAb (OKT3) 
 Anti-human CD28 mAb 
Janssen-Cilag GmbH, USA 
BD Biosciences, Germany 
51Chrome (Na251CrO4) Perkin Elmer, USA 
Cyclosporine A (Sandimmun) Novartis Pharma, Switzerland 
Cytokine Secretion Assay (IFN-gamma) Miltenyi Biotech, Germany 
DMEM medium Biochrom KG, Germany 
DMSO Roth, Germany 
EDTA Roth, Germany 
ELISPOT for human IFN-gamma Mabtech, Sweden 
Ethidiumbromide Calbiochem Behring Corp., Germany 
FCS (FBS) Biochrom KG, Germany 
Ficoll (1,077 g/ml) Biochrom KG, Germany 
L-Glutamine Biochrom KG, Germany 
GMCSF Promocell, Germany 
HEPES buffer Biochrom KG, Germany 
Hygromycine B Invitrogen, USA 
IL-1beta R & D Systems, USA 
IL-2 (Proleukine) Novartis Pharma, Switzerland 
IL-2 (recombinant) R & D Systems, USA 
IL-4 R & D Systems, USA 
IL-6 R & D Systems, USA 
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Ionomycine Sigma, USA 
Lumaplates96, white Perkin and Elmer, USA 
Mass Ruler™ MBI Fermentas, Germany 
MACS Microbeads 
Anti-CD3 
Anti-CD14 
Anti-PE 
Miltenyi, Germany 
MACS MS+ and RS+ columns Miltenyi, Germany 
MHC:peptide multimers for FACS Proimmune, England 
Sodium acide Sigma, USA 
Na-Pyruvate Biochrom KG, Germany 
PBS (10x) Gibco, Netherlands 
Penicillin/Streptomycine Biochrom KG, Germany 
Pfu Plus DNA Polymerase Roboklon, Germany 
PGE2 (Prostaglandin E2) Sigma, USA 
PHA-L Sigma, USA 
PMA Sigma, USA 
Propidium iodide (PI) Sigma, USA 
Protamine sulphate Sigma, USA 
Restriction Enzymes Fermentas, Germany 
Retronectin Takara Bio Inc. Japan 
RPMI 1640 Medium Biochrom KG, Germany 
SDS BioRAD, München; Serva, Heidelberg 
Seakem Agarose FMC, Rockland, USA 
TNF-alpha R & D Systems, USA 
Trypane blue  Biochrom KG, Germany 
Trypsin/EDTA Biochrom KG, Germany 
Kit System Manufacturer
GeneRacer Kit with Superscript III Invitrogen, USA
IFN-gamma cytokine secretion assay Miltenyi, Germany 
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IFN-gamma ELISA (Opteia) Becton Dickinson, USA 
IFN-gamma ELISPOT Mabtech, Sweden 
Invisorb Spin Cell RNA Mini Kit Invitek, Germany 
Invisorb Spin Plasmid Mini Kit Two Invitek, Germany
Invisorb Spin DNA Extraction Kit Invitek, Germany 
Invisorb Spin PCRapid Kit Invitek, Germany 
HiSpeed Plasmid Midi Kit Qiagen, Germany 
RNase-free DNase Set Qiagen, Germany 
RNeasy Mini Kit  Qiagen, Germany 
Instrument Manufacturer
6 
Biophotometer Eppendorf, Germany
Electrophoresis Serva, Germany 
Flow cytometer FACS Calibur Becton Dickinson, USA 
Irradiator OB29 STS GmbH, Germany 
Incubator Steri-Cult 200 Forma Scientific, Germany 
Luminometer Mithras LB 940 Berthold Technologies, Germany 
Magnetic mixer RCT basic Janke & Kunkel, Germany 
Megafuge 1.0 R Heraeus Christ, Germany 
Plastic consumables for cell culture TPP, Switzerland 
Spektral photometer DU 640 Beckman Instruments, Germany 
Power Supplies 
  Power Pack P25 
..Power Pack 300 
Biometra, Germany 
BioRAD, Germany 
Scintillation Counter (TopCount) NXT Perkin and Elmer, USA 
Varifuge 3.0 R Heraeus Christ, Germany 
Avanti J-25 Zentrifuge Beckman Instruments, Germany
Biofuge pico Heraeus Christ, Germany 
Ultracentrifuge L-60 Beckman Instruments, Germany 
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DNA Oligonucleotides 
All oligonucleotides were synthesized by Eurofins MWG Operon or TIB Molbiol. 
Primer name Sequence 
rev-Calpha RACE GGTACACGGCAGGGTCAGGGTTCT 
rev-nested-Calpha 
RACE 
CGGCAGGGTCAGGGTTCTGGATA 
rev-Cbeta RACE GTGGCCTTTTGGGTGTGGGAGAT 
rev-nested-Cbeta 
RACE 
GGTGTGGGAGATCTCTGCTTCTGAT 
fwd-0.3GG3beta ATATTTAAGCGGCCGCAGCTACCATGGGCCCCC 
fwd -5G10beta ATATTTAAGCGGCCGCGGAGCTGAAATGGGCACCA 
fwd -9F8beta TTATATTTAAGCGGCCGCAATACTGCCATGGGCACCA 
rev-TCRCalpha TGGAATTCTCAGCTGGACCACAGCCGCAGC 
rev-TCRCbeta1 TGGAATTCTCAGAAATCCTTTCTCTTGACC 
rev-TCRCbeta2 TGGAATTCCTAGCCTCTGGAATCCTTTCTC 
fwd-p2A-0.3GG3alpha AACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGT 
CCCATGGAGACTCTCCTGAAAGTGCTTTCA 
fwd-p2A-5G10alpha AACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGT 
CCCATGGAGACCCTCTTGGGCCTGCTTATC 
fwd-p2A-9F8alpha AACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGT 
CCCATGAAGTTGGTGACAAGCATTACTGTA 
rev-p2A-0.3GG3beta TTCCACGTCTCCTGCTTGCTTTAACAGAGAGAAGTTCGTGGCGCCGCTT
CCGAAATCCTTTCTCTTGACCATGGCC 
rev-p2A-5G10beta TTCCACGTCTCCTGCTTGCTTTAACAGAGAGAAGTTCGTGGCGCCGCTT
CCGAAATCCTTTCTCTTGACCATGGCC 
rev-p2A-9F8beta TTCCACGTCTCCTGCTTGCTTTAACAGAGAGAAGTTCGTGGCGCCGCTT
CCGCCTCTGGAATCCTTTCTCTTGACC 
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2.2 Methods 
2.2.1 Cell Culture and Ccell-based Assays 
Cell Lines 
EBV-transformed LCLs were established by culturing peripheral blood mononuclear cells 
(PBMCs) of serologically class I-typed donors with supernatant from the marmoset cell 
line B95-8 in the presence of 25 µg/ml cyclosporine A in RPMI 1640 
containing 20 % FCS / glutamine / gentamycin (or spontaneous outgrowth of LCL under 
cyclosporine A treatment without virus supernatants. See table 2). 
The packaging cell line HEK293T was cultured in DMEM supplemented with 10 %  FCS. 
Jurkat76 (J76), Jurkat/MA (JMA) cells and the human B lymphoblastoid cell lines were 
cultured in RPMI 1640 medium supplemented with 10% FCS, 1 mM HEPES, 2 mM 
glutamine and 100 units / mL penicillin / streptomycin (and hygromycine B 500 µg / ml 
for JMA). J76 cells are TCR alpha and TCR beta deficient but express all CD3 
components. JMA reporter cells lack an endogenous TCR beta chain and carry an NFAT-
luciferase gene (NFAT = nuclear factor of activated T cells) with hygromycine B selection 
marker. 
All cells were maintained as suggested by the German Resource Centre for Biological 
Material (DSMZ). LCLs were previously established in our group or kindly provided by 
A. Moosmann (German Research Center for Environmental Health, Munich). A list of all 
LCLs used in experiments is provided in table 2. 
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Tab. 2: HLA types of LCL lines used 
Name HLA class I (A, B) HLA class II 
LCL1 A*02,*26; B*13,*27 DRB1*07; DRB4*pos; DQB1*02 
LCL2 A*32,*68; B*44 DRB1*01,*11; DRB3*pos; DQB1*03, *05 
LCL3 A*01,*31; B*08,*4002 DRB1*0301,*11;DRB3*pos; DQB1*02,*03 
LCL4 A*02,*24; B*15 DRB1*11,*13; DRB3*pos; DQB1*03,*06 
LCL5 A*24; B*08; B*51 DRB1*0301,*13; DRB3*pos; DQB1*02,*06 
LCL6 A*01; B*08 DRB1*0301; DRB3*pos; DQB1*02 
GOELK A*11, *24; B13, *38 DR7, DR12, DR52, DR53, DQ2, DQ3
MDB1 A*01, *11; B*08, *1501 DRB1*03, *11; DQB1*02, *03 
FSB1 A*24, *26; B*7, *38 DR11, DR15, DQ3, DQ6, DRB3, DRB5 
JNB3 A*01, *0201; B*07 ,*4001 
STA01 A*0201; B*0702, *1501 DRB1*1301, *1501 DQB1*0602, *0603 
Other cells: 
B95-8 [102] (ATCC: VR-1492) 
HEK293T [103] (ATCC: CRL-11268) 
Jurkat76 (J76) [104] stably transfected with human CD8 alpha 
Jurkat/MA (JMA) [105] 
Primary cells (PBLs and DCs) were isolated from healthy donors’ whole blood (donors: 1, 
2, 3, 4, 5). 
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General Cell Culture Technique 
Cells were cryopreserved at 0.5 – 1 x 107 cells / ml in cryomedium containing 
(90 % FCS / 10 % DMSO) with gradual temperature decrease in isopropyl alcohol cryo 
boxes over night before transfer to gaseous phase nitrogen. For thawing, cryotubes were 
warmed in a 37°C water bath and the cell suspension taken up and washed in PBS before 
being resuspended in 10 ml of warm medium. All centrifugation steps were performed at 
300 x g unless stated otherwise. Live cell numbers were determined using Neubauer 
Improved counting chambers. Trypane blue was added for dead cell discrimination. 
Preparation of PBMCs from Whole Blood 
PBMCs were isolated using Ficoll-Hypaque density gradient centrifugation. Lymphocytes 
and monocytes were thereby separated from plasma, erythrocytes and granulocytes 
according to differences in their density. Approximately 30 ml of diluted blood (1:2 in 
PBS / 2mM EDTA) were layered on top of 20 ml Ficoll solution and then centrifuged at 
400 x g for 30 minutes before stoppage by swinging out without brake. The interphase 
containing PBMCs was collected and washed twice with PBS to yield ready-to-use 
PBMCs. 
Generation of Mature Dendritic Cells and Peptide Load 
DCs were generated from PBMCs by positive selection with CD14 microbeads on MS 
columns  and subsequent culturing in RPMI 1640 supplemented with 10 % FCS, GMCSF 
(1000 units / ml) and IL-4 (1000 units / ml) in 6-well plates and 2 x 106 cells per well (day 
0). GMCSF was added on days 2 and 4 to (1000 units / ml). On day 7, medium was 
conditioned by addition of GMSCF (1000 units / ml), IL-4 (500 units / ml), IL-6 
(1000 units / ml), IL-1-beta (10 ng / ml), TNF-alpha (10 ng / ml) and PGE2 (1 mg / ml). 
Peptide pulse of DCs for stimulation of EBV-reactive T cells was carried out on day 9. 
DCs were pulsed at 105 – 106 cells / ml and 10 µM of peptide for one hour at 37° C. 
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Generation of EBV-specific T cell Clones 
2 x 105 peptide-pulsed DCs were used to stimulate 2 x 106 T cells in 2 ml RPMI 1640 
supplemented with 5 % human AB serum and IL-7 (5 ng / ml). After 2 days recombinant 
human IL-2 (100 IU / ml) was added. Stimulation was repeated weekly with 2 x 105
peptide-pulsed DCs and IFN-gamma secretion was determined by cytokine secretion 
assay. For T cell clone generation, specific T cells were isolated using HLA:peptide 
multimeric complexes, anti-PE antibodies coupled to magnetic beads, RS+/MS+ columns 
and MiniMACS separator. Positively selected T cells were cloned by limiting dilution and 
expanded using a previously described polyclonal T cell stimulation protocol [15] using 
PHA-L (1 µg / ml), IL-2 (150 IU/ml) and irradiated feeder cells (PBMCs: 105 / well and 
allogenic LCLs: 2 x 104 / well). PBMCs received 3,000 rad and LCLs 24,000 rad of 
irradiation before being used as feeder cells. For limiting dilution one half plate was 
prepared with 10 T cells per well, three plates with one T cell per well and eight plates 
with 0.3 T cells per well. Growing populations were split with IL-2 additions as 
previously. 
IFN-gamma ELISPOT Split-Well Screening Assay 
After two weeks of expansion (in addition to lag time of approximately 10 days) T cells 
were tested in an ELISPOT split-well assay for IFN-gamma secretion upon stimulation 
with specific EBV (EBNA2-TVF) peptide pulsed onto autologous DCs. 2 x 104 T cells and 
2 x 103 peptide-pulsed DCs were used per well and incubated over night. The ELISPOT 
was performed according to the manufacturer’s protocol. Peptide-specific T cells were 
expanded with the same protocol and after 2 weeks tested for phenotype by FACS and for 
functional T cell affinity in peptide titration ELISPOT assay. PHA-L (3 µg/ml), SEB 
(5 µg/ml) and P/I/S (PMA = 5 ng/ml; Ionomycin = 1 µg/ml; SEB = 5 µg/ml) were used as 
positive controls. 
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IFN-gamma ELISPOT 
To test the functional T cell avidity of different T cell clones, autologous DCs loaded with 
EBV peptides were used to induce IFN-gamma secretion in an ELISPOT assay. The 
ELISPOT was performed as described [106]. Briefly, 2,000 peptide-pulsed DCs were 
added to 2 x 104 T cells per well after being pulsed with 10-fold peptide dilutions, ranging 
from 10,000 nM to 0.01 nM, including a control with no added peptide. Additional 
controls were peptide-pulsed DCs alone, irrelevant peptide as well as T cells alone. P/I/S 
served as a positive control. Incubation was carried out over night. 
IFN-gamma Secretion Assay 
After three hours of stimulation, approximately 200,000 T cells from the coculture with 
peptide-pulsed DCs were tested in an IFN-gamma secretion assay. The assay was 
performed as recommended by the manufacturer. Unstimulated cells served as negative 
controls. As a positive control P/I/S stimulated T cells were measured. Propidium iodide 
(PI) staining was included for dead cell discrimination. For FACS analysis, gates were set 
on propidium iodide-negative and CD4-positive cells. 
IFN-gamma ELISA 
HLA-matched and mismatched LCLs were pulsed at room temperature (RT) with specific 
peptide or control peptide for one hour at peptide concentrations ranging from 10 µM to 
0.0001 µM. 105 T cells were cocultured overnight (16-20 hours) with 105 peptide-pulsed 
LCLs and the supernatant harvested for subsequent analysis or frozen at -20 °C. ELISA 
procedure was performed according to manufacturer’s protocol.
NFAT Luciferase Assay for TCR Function 
TCR-transduced JMA cells were sorted using human anti-CD3 microbeads according to 
the manufacturer’s protocol. Double staining with tetramers and anti-CD3 antibodies 
confirmed successful enrichment of TCR-positive JMA cells. HLA-matched and 
mismatched LCLs were pulsed at room temperature with specific peptide or control 
peptide for 1 hour at peptide concentrations ranging from 10 µg to 0.01 µg. 105 T cells 
were cocultured overnight (16-20 hours) with 105 peptide-pulsed LCLs. After addition of 
25 µl of Bright-Glo reagent luminescence was measured in a luminometer. Non-pulsed 
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LCLs as well as specific peptide loaded onto HLA-mismatched LCLs and irrelevant 
peptide loaded onto HLA-matched LCLs served as negative controls. 
  
51Cr release Cytotoxicity Assay 
LCL targets were incubated with 100 µCi of Na251CrO4 (1 mCi / ml, sterile stock) for one 
hour at 37° C with or without prior peptide pulse (10 µM; 1 hour; RT). The targets were 
washed 4 times and 1 x 104 target cells were added to each well with effectors in 
RPMI/10%FCS. Triplicate wells were prepared. Spontaneous release and total release 
samples were prepared by adding the targets to wells containing medium alone or a final 
concentration of 0.33 % sodium dodecyl sulphate respectively (sextuplicate each). After 
five hours of incubation 50 µl of supernatant were harvested per well and transferred onto 
lumaplates and measured the next day in a scintillation counter. The percentage of specific 
lysis was calculated as follows: 100 x [(release by experimental well – spontaneous 
release) / (total – spontaneous release)]. Spontaneous release was between 15 to 25 % of 
the total release. The effector:target ratios were calculated based on the percentage of 
tetramer-positive T cells after retroviral transduction without enrichment. 
Transient Three-Plasmid Transfection for Production of Virus Supernatants 
Cells were transiently transfected using calcium phosphate precipitation. One day before 
transfection, 7 to 9 x 105 HEK293T cells in a volume of 3 ml were allocated to each well 
of a 6-well tissue culture plate. For each transfection, 150 µl of transfection buffer (per 
liter: 16 g NaCl, 740 mg KCl, 500 mg NaHCO3, 10 g Hepes, pH 6.75) were added 
dropwise to a precipitation mix of 150 µl containing a total DNA amount of 18 µg (1:1:1 
ratio of TCR retroviral vector, pcDNA3.1gag/pol and pALF-10A1GaV) as well as 15 µL 
CaCl2. During addition of the transfection buffer, the setup was being continuously 
vortexed at medium speed. 15 minutes were allowed for precipitate formation at room 
temperature before adding the whole mix to one well of previously seeded HEK293T cells. 
After 6 hours of incubation, medium was aspirated and replaced by fresh medium. After 
48 hours the supernatant was harvested and cleared of cells and debris by filtering through 
a 0.45 µm filter before being used for transduction of cells. 
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Transduction of Cell Lines and Peripheral Blood Lymphocytes 
T cell lines were transduced in 24-well non-tissue culture plates coated with RetroNectin 
(25 µg / ml Retronectin for 2 hours, block 30 minutes with 2 % BSA, wash with 
PBS / 2.5 % Hepes). 2 x 105 T cells / ml / well were transduced with 1 ml of virus 
supernatant by spinoculation (800 x g; 90 min, 32 °C) in the presence of protamine 
sulphate (4 µg / ml). 
Peripheral blood lymphocytes were transduced two times by spinoculation. The cells were 
stimulated with plate-bound anti-CD3 and anti-CD28 antibodies prior to transduction. 
Coating of 24-well plates for T cell stimulation was performed for 2 hours at 37° C with 
5 µg / ml anti-CD3 and 1 µg / ml anti-CD28 antibody, followed by blocking with 2 % 
bovine serum albumine for 30 minutes and washing with PBS. T cells were stimulated at 
106 cells / ml / well in the presence of 100 IU / ml IL-2. The first transduction was 
performed on day 2 after isolation and 48 hours of stimulation with plate-bound anti- CD3 
and anti- CD28 antibodies. The transduction was performed as described for cell lines. 
After 24 hours, T cells were removed from anti CD3/CD28-coated plates and retransduced 
at 3 x 105 cells / ml / well plus another 1 ml of retrovirus supernatant in RetroNectin-
coated plates as described above. Expression of introduced TCRs was assessed after 72 
hours using flow cytometric analysis with PE-labelled multimers. Transduced primary 
T cells were expanded for 8-10 days with medium containing 100 IU / ml IL-2. Before 
functional assays were performed, transduced T cells were cultured in medium containing 
10 IU / ml IL-2 (low IL-2) for two more days. 
2.2.2 Molecular Biology 
General Molecular Biology Techniques 
DNA fragments were separated using agarose gel electropheresis with 1 % agarose gels 
and TAE buffer (Tris-acetate EDTA). Ethidiumbromide (0.05 µg/ml) was used to stain 
DNA. Molecular weight markers from New England Biolabs (2-log DNA ladder) as well 
as from Fermentas (MassRuler) were used for estimation of size and concentration. All 
restriction enzymes were purchased from Fermentas and incubated in recommended 
buffers. PCR reactions were run using PfuPlus high-fidelity proof-reading polymerase. 
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Cloning of TCR Genes and Construction of Retroviral Vectors 
The TCR alpha and TCR beta chain genes of LMP2a and EBNA3a-specific T cells were 
identified by GeneRacer RACE-PCR system and cloned into the retroviral vector MP71-
PRE [107]. Briefly, total-RNA was prepared from 106 T cell clone cells using RNeasy 
Mini Kit and linked to the GeneRacer cassette according to the manufacturer’ s protocol. 
cDNA was synthesized with SuperScript III reverse transcriptase using gene-specific 
reverse primers and nested primers. Subsequently, RNase H digest and PCR amplification 
were performed. The bulk product of the first nested-RACE PCR was sequenced to 
identify variable and constant TCR gene segments using IMGT/V-Quest and 
IMGT/Junction Analysis [108]. Full-length TCR chains were then amplified using PCR 
with full-length primers and cloned into MP71 retroviral vectors [107]. To obtain the TCR 
beta-IRES-TCR alpha construct, both TCR chains were first cloned into a pBS-IRES 
vector before transferring the cassette to the MP71 vector. Single-chain and p2A-linked 
TCR gene cassettes were directly cloned into the MP71 vector. To assemble the TCR beta-
2A-TCR alpha construct, recombinant PCR was performed. Both chains were amplified in 
full length with long overhangs coding for the 2A peptide linker. Homologous 
recombination then allowed amplification of the whole cassette. 
Plasmids and Primers 
The plasmid vector pcDNA3.1MLVg/p encodes the Mo-MLV gag-pol gene (kind gift from 
C. Baum) and the plasmid vector pALF10A1GaV contains the MLV-10A1 env gene [109]. 
The retroviral vector MP71-PRE has been described before [107]. MP71-TCR-LMP2a 
(LMP2a-specific), MP71-TCR-EBNA3a (EBNA3a-specific) and GFP-bearing (MP71-
GPRE) constructs were generated as single-chain vectors (sc) or with an IRES site to link 
TCR alpha and TCR beta chains (TCR beta-IRES-TCR alpha). 
DNA Sequencing 
DNA Sequencing was performed as contract service by INVITEK Biotechnology and 
Biodesign LTD. (Berlin, Germany) and Eurofins MWG Operon LTD (Martinsried, 
Germany). 
Codon Optimization 
Codon optimization was performed by GeneArt AG (Regensburg, Germany). 
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2.2.3 Peptides, Multimers, Antibodies 
Peptides and Multimers 
The synthetic peptides were synthesized in the lab of Dr. Henklein (Charité) 
(FLRGRAYGL (HLA-B8 / EBNA3A325-333) [110] and CLGGLLTMV 
(HLA-A2 / LMP2a426-434) [111]) or by Wita GmbH, Germany (FLRGRAYGL, 
CLGGLLTMV and class II TVFYNIPPMPL (EBNA2280-290) [112]). All peptides were 
> 95 % pure as seen by mass spectrometry and high-performance liquid chromatography 
(HPLC). Stock solutions in water and dimethyl sulfoxide (DMSO final concentration 
50 %) were kept at -80° C. Tetrameric peptide-MHC class I complexes were generated 
mainly by K. Sebelin as previously described [113]. Multimers were available as 
synthesized in our group or purchased from Proimmune. No multimer was available for the 
class II-restricted epitope EBNA2-TVF. 
Antibodies 
The antibodies used for TCR Vbeta panel analysis of the CD4+ T cell clones were 
purchased from Immunotech, All other antibodies were purchased from BD Bioscience, 
Germany. 
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3 Results 
3.1 CD8+ T cell Clones for TCR Isolation 
EBV-specific CD8+ T cell clones had been prior isolated in our group and were readily 
available for isolation of their TCR genes. The antigens used to establish the EBV-specific 
T cells shown in this work, represent one immunodominant (EBNA3a-FLR) as well as one 
subdominant (LMP2a-CLG) T cell epitope. The HLA restrictions of the chosen EBV 
epitopes cover a major fraction of the Caucasian population (LMP2a-CLG HLA-A2: 
~ 50%; EBNA3a-FLR HLA-B8: ~ 20%). The CD8+ T cell clones chosen have shown 
monospecificity and antigen-specific affinity (Fig. 4). All cells bound tetramer and 
released IFN-gamma in response to stimulation with peptide concentrations as low as 
10 nM. Irrelevant tetramer was not bound to the cell surface (not shown). 
Fig. 4: Specificity and affinity of CD8+ T cell clones 5G10LMP2a and 9F8EBNA3a. A) 
Peptide-pulsed DCs were used for generation of LMP2a-specific and EBNA3a-specific T cell 
clones. Double staining of T cell clones 5G10LMP2a and 9F8EBNA3a with anti-CD8 antibody and 
corresponding tetramer demonstrated monospecificity of the obtained T cell lines. B) 5G10LMP2a 
and 9F8EBNA3a-specific CD8+ T cell clones were tested by ELISPOT for IFN-gamma secretion 
in response to the indicated peptide concentrations. Peptide concentrations of 10 µM were 
sufficient to trigger IFN-gamma release. 
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3.2 Isolation of EBV-specific CD4+ T cells 
In order to obtain EBV-specific TCRs for transfer into primary T cells, T cell clones were 
generated using peptide-pulsed DCs for stimulation and expansion. In addition to the 
already established CD8+ T cell clones, we sought to establish CD4+ T cell clones that 
were able to recognize EBV antigens. We chose peptide-pulsed DCs for use as APCs, due 
to their superb ability to activate T cells. It had furthermore been shown that DCs can be 
superior to LCLs in stimulating EBV-specific T cells that can theoretically target any 
desired epitope instead of relying on the epitopes naturally expressed dominantly on LCLs. 
3.2.1 EBV-specific Stimulation and Enrichment of T cells 
We decided to establish T cell lines targeting EBNA2-derived peptide TVF 
(TVFYNIPPMPL = EBNA2280-290) by serial stimulation with peptide-pulsed DCs. EBNA2 
is expressed in EBV latency stages II and III. Also, this epitope was reported to be 
compatible with numerous HLA class II alleles thus potentially providing widespread 
applicability of a corresponding TCR in many patients [112]. In cytokine secretion assays, 
only propidium iodide (PI)-negative and CD4+ lymphocytes were analysed; appropriate 
gates were set during flow cytometric analysis. We generated mature autologous DCs from 
donor 1 by in-vitro maturation and loaded them with EBNA2-TVF peptide. Such 
autologous cells were used to carry out three rounds of stimulation allowing one week of 
time between the stimulations. After two weeks the percentage of IFN-gamma secreting 
T cells had steadily increased to 0.68 % whereas after three weeks no further enrichment of 
EBNA2-TVF-specific T cells could be achieved (fig. 5). Therefore we performed a 
cytokine secretion assay with subsequent MACS enrichment of IFN-gamma secreting cells 
via anti-PE microbeads. The IFN-gamma secreting cells were then cloned by limiting 
dilution. Limiting dilution yielded numerous proliferating T cell populations that were 
expanded by addition of IL-2. 
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Fig. 5: Enrichment of EBV-specific CD4+ T cells. A) After weekly stimulation with peptide-
pulsed DCs, bulk cultures were tested for the presence of EBNA2-TVF-specific T cells. Cytokine 
secretion assays were performed to assess IFN-gamma secretion upon antigen-specific activation. 
FACS analysis shows live and CD4+-gated lymphocytes. A steady increase in the percentage of 
EBNA2-TVF-specific T cells was detected after each restimulation round. B) MACS separation 
was performed to enrich IFN-gamma secreting cells after two weeks. Effective enrichment was 
monitored by FACS analyses showing a depletion of IFN-gamma-secreting cells in the second 
flowthrough. IFN-gamma-secreting cells made up about 38 % of the IFN-gamma-positive fraction. 
This population was allocated to 96-well plates in dilution of 10, 1 and 0.3 cells per well for 
limiting dilution. Irrelevant peptide loaded onto DCs was included as negative control (-ctrl). 
PMA/Ionomycine/SEB (P/I/S)-treated cells were used as positive control (+ctrl). 
3.2.2 Characterization of EBV-specific T cell Lines 
3.2.2.1 Specific Responsiveness to EBNA2-TVF Epitope 
To determine whether the T cell lines that we had obtained from limiting dilution 
recognized the desired epitope, an IFN-gamma ELISPOT assay was performed in a split-
well strategy, incubating each T cell line with or without peptide. This way, we had an 
easy-to-discriminate readout to determine peptide specificity of each T cell line (table 3, 
fig. 6). Although all responding T cell lines were analysed, data shown hereafter only 
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cover results obtained from the T cell line termed 0.3GG3EBNA2 which arose from a 
dilute well (0.3 cells per well in limiting dilution). 
Tab. 3:  Experimental scheme of split-well ELISPOT assay for IFN-gamma 
+ 
TVF 
- 
TVF 
+ 
TVF 
- 
TVF 
+ 
TVF 
- 
TVF 
+ 
TVF 
- 
TVF 
+ 
TVF 
- 
TVF 
+ 
TVF 
- 
TVF 
1 2 3 4 5 6 7 8 9 10 11 12 
A 10A F4 1B C6 1C F3 1D D7 1E C8 0.3D B6 
B 10A F5 1B D2 1C F4 1D E4 1E E11 0.3D C3 
C 1A F3 1B E7 1C F9 1D F4 1E F3 0.3D G2 
D 1A F8 1B F4 1C F11 1E B8 1E F5 0.3E F11 
E 1A F9 1C B4 1D B11 1E C4 0.3B G8 0.3G C4 
F 1A F11 1C D3 1C G10 1E C6 0.3C B8 0.3G G3 
G 1B C4 1C C9 1D C2 1E C7 0.3C C4 Blank 
H PBMC + SEB (1 µg/ml) 
PBMC + SEB 
(5 µg/ml) 
PBMC + PHA 
(3 µg/ml) 
10A F4 + 
PMA/Iono./SEB 
(5ng/ml/1 µg/ml/ 
5µg/ml) 
10A F4 + SEB 
(5 µg/ml) Blank 
Fig. 6: Split-well screening for antigen-specific CD4+ T cell lines. After limiting dilution 
cloning, proliferating populations were tested in a split-well IFN-gamma ELISPOT assay for their 
responsiveness to 3-hour stimulation with EBNA2-TVF peptide-pulsed DCs. One well of each 
growing T cell population was divided in two and incubated with DCs (with or without peptide 
pulse). PMA/Ionomycin/SEB–treated PBMCs (105 per well) served as positive controls. Further 
positive controls were PBMCs treated with SEB or PHA alone at the indicated concentrations. 
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3.2.2.2 Homogeneity of EBNA2-TVF-specific T cell Populations 
The peptide-responsive T cell line 0.3GG3EBNA2 described in the previous section was 
then analysed in an IFN-gamma cytokine secretion assay to estimate homogeneity and 
specificity of the isolated T cells. The assay showed that all cells of the population could 
be activated upon stimulation with EBNA-TVF peptide-pulsed DCs (fig. 7). The whole 
population showed a clear response to specific peptide whereas irrelevant peptide did not 
have any effect. Since this fact alone does not allow reliable conclusions with regard to 
monoclonality of the T cell line, TCR Vbeta monoclonal antibody panel analysis was 
performed. This showed that all cells of the 0.3GG3 T cell line expressed the TCR 
Vbeta14 chain as an indicator of monoclonality (fig. 8). 
Fig. 7: 0.3GG3EBNA2 CD4+ T cells secrete IFN-gamma upon antigenic stimulation. 
0.3GG3EBNA2 T cells were stimulated with DCs loaded with EBV-derived peptide EBNA2-TVF 
as well as irrelevant peptide (negative control) at 5 ng/ml for 3 hours. IFN-gamma production was 
measured by IFN-gamma secretion assay. P/I/S-stimulated T cells served as positive control (+ctrl). 
The isolated T cell line 0.3GG3 showed complete response to stimulation with EBNA2-TVF 
peptide as well as with P/I/S. Irrelevant peptide (-ctrl) did not lead to IFN-gamma secretion. 
Results 3.1/.2EBV-specific T cell clones
44
Fig. 8: TCR Vbeta analysis of 0.3GG3EBNA2 T cell line. A panel of TCR Vbeta-specific 
monoclonal antibodies was used to further assess the monoclonality of the 0.3GG3EBNA2 T cell 
line. The cells almost completely expressed the Vbeta14 TCR chain. 
3.2.2.3 Phenotype of 0.3GG3EBNA2 T cell Line 
Further insight into the cell population’s characteristics was obtained from surface 
stainings for CD3, CD4, CD54, CD45 RO/RA and CCR7 (fig. 9). The cells express CD3 
and CD4 as well as CD45RO which describes 0.3GG3EBNA2 cells as effector- or 
memory-type CD4+ T cells. CCR7 and CD45RA were not expressed. 
Fig. 9: Phenotypic analysis of 0.3GG3EBNA2 T cells. Surface expression of CD3, CD4, CD54, 
CD45 RA/RO as well as CCR7 was measured on 0.3GG3 T cells using monoclonal antibodies and 
FACS. The T cells expressed CD3, CD4, CD45RO and CD54, but not CCR7 and CD45RA. 
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3.2.2.4 Avidity of 0.3GG3EBNA2 T cell Line 
In an ELISPOT assay with titrated amounts of peptide loaded onto HLA-matched target 
cells (autologous DCs), the T cells were able to recognize targets pulsed with peptide at a 
minimum concentration of 10 nM to produce detectable amounts of IFN-gamma (fig. 10). 
This value is comparable to those achieved by the CD8+ T cell clones. 
Fig. 10: Avidity of 0.3GG3 CD4+ T cells. IFN-gamma ELISPOT was utilized to determine the 
minimal peptide concentration threshold needed for T cell activation. Autologous DCs pulsed with 
peptides at different concentrations served as APCs. 0.3GG3EBNA2 T cells recognized target cells 
pulsed with peptide concentrations of 10 nM or more. 
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3.2.2.5 Cytotoxicity of 0.3GG3EBNA2 T cell line 
0.3GG3EBNA2 T cells had the ability to kill antigen-positive cells. We showed this in a 
standard chromium release cytotoxicity assay demonstrating efficient lysis of EBV-
transformed and HLA-matched LCLs in an effector:target (E:T) ratio-dependent manner. 
However, antigen-specific lytic activity was dependent on external addition of specific 
peptide (fig. 11). 
Fig. 11: Ag-specific cytotoxic activity of 0.3GG3EBNA2 CD4+ T cells. In a standard five-hour 
chromium release assay, 0.3GG3EBNA2 T cells lyse TVF peptide-loaded HLA-matched EBV-
transformed LCLs in an E:T ratio-dependent manner. Non-pulsed LCLs were not lysed. 
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3.3 Molecular Cloning of EBV-specific TCR Alpha and Beta Genes 
To identify the unknown T cell receptor alpha and beta chain genes, RNA ligase-mediated 
RACE PCR using total mRNA from each T cell clone as starting material was performed. 
In case of non-monoclonal T cell populations, the initial RACE PCR would have amplified 
all TCR chains present in the cDNA pool because constant-region-specific reverse primers 
and non-specific forward primers were used. We sequenced the TCR chain RACE PCR 
product in bulk and found only one alpha and one beta chain sequence for each clone 
which confirmed cellular monoclonality (data not shown). The obtained TCR sequences 
were identified using IMGT/V-Quest [108]. The CDR3 regions for TCR-LMP2a and TCR-
EBNA3a as well as CD4+-derived TCR-EBNA2 are shown in figure 12. The TCRs from 
clone 5G10LMP2a and 0.3GG3EBNA2 have yet undescribed alpha and beta chain 
combinations. The TCR from clone 9F8EBNA3a, however, has been previously described 
and is commonly referred to as a “public TCR” frequently selected in persistent EBV 
infection [114]. Having isolated this TCR is a proof of principle for our method. The TCR 
was further used as a control in subsequent experiments. All TCRs were cloned into MP71 
retroviral vectors both as single-chain TCR constructs as well as double-chain constructs 
where both TCR chains are linked by an IRES element (TCR beta-IRES-TCR alpha). In 
figure 13 a work-flow chart summarizing the TCR cloning of each T cell clone is shown. 
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Fig. 12: CDR3 regions of isolated EBV-specific TCRs. TCRs sequences from CD8+ T cell 
clones 5G10LMP2a and 9F8EBNA3a as well as CD4+ T cell clone 0.3GG3EBNA2 were identified 
using RACE PCR. The length of each CDR3 region is expressed in the number of amino acids 
(AA). Nucleotide and translated sequences as well as specific V, D and J regions are shown. N-
regions contribute to so-called junctional diversity by enzymatic addition or deletion of single 
nucleotides to the extremities of the coding V, D or J genes. The CDR3 loop of a TCR is the most 
variable part and directly involved in the recognition of HLA-bound antigen.
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Fig. 13: Experimental procedure flow chart for TCR cloning. Since they had already been 
isolated at start, CD8+ T cell clones 5G10LMP2a and 9F8EBNA3a were instantly available for 
TCR transfer. Therefore, the TCRs isolated from these clones (TCR-EBNA3a and TCR-LMP2a) 
were used in the characterization of the TCR expression and function in donor T cells. Up to this 
point the vectors contained a TCR beta-IRES-TCR alpha configuration. As soon as it was 
completely identified, TCR-EBNA2 from the newly established CD4+ clone was directly 
integrated in optimization measures. Final analyses were carried out using the two novel TCR 
constructs (TCR beta-2A-TCR alpha configuration with codon-optimized TCR chains): one CD8+- 
and one CD4+ T cell-derived TCR (TCR-LMP2a and TCR-EBNA2) 
comparative expression analyses
functionality of optimized TCRs in primary cells
principle TCR function in primary cells
principle antigen-specific
TCR expression and function in cell lines
screening of EBV+ target cells
optimized vs. non-optimized TCRs
vector and gene optimization
molecular cloning of TCR genes
EBV-specific CD8+ T cell clones (prev. isolated)
EBV-specific CD4+ T cell clone (new isolation)
TCR-EBNA2 TCR-LMP2a TCR-EBNA3a
TCR-EBNA2 TCR-LMP2a TCR-EBNA3a
TCR-EBNA2 TCR-LMP2a TCR-EBNA3a
TCR-EBNA2 TCR-LMP2a
TCR-EBNA2 TCR-LMP2a
TCR-LMP2a TCR-EBNA3a
TCR-LMP2a TCR-EBNA3a
TCR-LMP2a TCR-EBNA3a
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3.4 TCR Transfer into T cell Lines and Primary T cells 
3.4.1 CD8-derived TCR Transfer into TCR-deficient T cell Lines 
Since the CD8+ T cell clones were already available at start, their TCRs were isolated 
before CD4+ T cell clones were established. Therefore, initial analyses and technical 
developments are based on these two TCRs only (fig. 13). TCR retroviruses (TCR beta-
IRES-TCR alpha configuration) were generated and used to transduce the human T cell 
line J76 which lacks surface expression of an endogenous TCR. EBV-specific TCRs were 
introduced by retroviral transfer and TCR expression was determined using tetramers. As 
J76 cells express all components required for proper TCR assembly except for endogenous 
alpha and beta TCR chains, surface expression of introduced TCR chains is facilitated due 
to the lack of competition by endogenous chains. In the experiment shown in figure 14, 
tetramer analyses showed correct TCR expression on J76 cells at 40.04% (TCR-LMP2a) 
and 32.43% (TCR-EBNA3a). In JMA cells the endogenous beta chain is deleted, but with 
an endogenous alpha chain being present, competition of the endogenous and the 
introduced alpha chains for pairing with the introduced beta chain for TCR formation 
occurs. In JMA cells transduced with the same viral supernatants we found 45.22% (TCR-
LMP2a) and 26.12% (TCR-EBNA3a) of antigen-specific TCR expression. The expression 
levels in JMA cells were comparable to those in J76 cells, thus indicating the dominance of 
the introduced TCR alpha chain over the endogenous alpha chain of JMA cells for 
functional TCR formation with the introduced beta chain. Although transduction efficiency 
is prone to inter-experimental variation, in each experiment, expression levels in JMA and 
J76 were consistently in similar range. 
3.4.1.1 TCR Function in Jurkat/MA Reporter Cell Line 
Antigen specificity and basic functionality of TCR-transduced cells was assessed in JMA 
cells. These cells bear an NFAT-driven luciferase gene and can therefore serve as indicator 
cells for T cell activation via TCR signaling. TCR-transduced JMA cells were sorted by 
MACS to obtain homogenous CD3+ populations of TCR-bearing cells. TCR-LMP2a 
seemed to have higher peptide sensitivity than TCR-EBNA3a when introduced into JMA 
cells. The lowest peptide concentration tested (0.01 µM) was sufficient to stimulate TCR-
LMP2a-transduced cells, whereas a peptide concentration of 0.1 µM resulted in only a 
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weak signal for TCR-EBNA3a-transduced cells (fig. 15A). Altogether, T cell activation as 
seen by luciferase expression was mediated via each introduced TCR after coculture with 
peptide-pulsed HLA-matched LCLs as targets, whereas no T cell activation was seen when 
irrelevant peptide or HLA-mismatched LCLs were used (data not shown). CD4+ T cell-
derived TCR-EBNA2 was also tested in a luciferase assay with JMA cells showing that 
antigen-specific function could be transferred by the TCR (fig. 15B). Negative controls 
(irrelevant peptide loaded onto HLA-matched LCL as well as specific peptide loaded onto 
HLA-mismatched LCL) did not result in TCR-mediated cell activation and are not shown. 
Fig. 14: Expression of CD8+ T cell-derived EBV-specific TCRs. 2 x 105 T cells were 
transduced by spinoculation with TCR retroviruses in RetroNectin-coated 24-well plates. 
(A) Transduction efficiency in TCR alpha/beta-deficient Jurkat76 cells as well as (B) TCR beta-
deficient Jurkat/MA cells was assessed by multimer staining 72 hours after transduction. 
Comparable TCR expression levels were measured for both cell lines demonstrating correct 
assembly of the introduced TCR chains as well as dominance of each introduced alpha chain over 
the endogenous alpha chain of Jurkat/MA cells. Overlay histograms show specific multimer 
binding compared to multimer staining of untransduced cells as a negative control. Bicistronic 
vectors containing an IRES site were used for transduction. 
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Fig. 15: TCR transfer confers antigen-specific function to JMA cells. After overnight coculture 
of 105 TCR-transduced, CD3+ Jurkat/MA cells with the same number of peptide-pulsed, HLA-
matched LCLs, luminescence was measured after addition of Bright-Glo reagent. LCLs were prior 
loaded with titrated amounts of peptide. A) CD8+ T cell derived TCRs TCR-LMP2a (vs. LCL4) 
and TCR-EBNA3a (vs. LCL3) transduced into JMA cells. B) CD4+ T cell derived TCR-EBNA2 
transduced into JMA after coculture with peptide-pulsed LCL4 cells. 
3.4.2 Transfer of CD8+ T cell-derived TCRs into Primary T cells 
3.4.2.1 TCR Expression in Primary T cells 
Although we had achieved good TCR expression in TCR-deficient cell lines, expression 
was quite low in primary T cells. To analyze whether or not TCR retroviruses with a 
different arrangement of the TCR expression cassette would improve the transduction 
efficiency, single-chain TCR retroviruses were generated in addition to the prior utilized 
IRES-containing bicistronic vectors. In order to compare IRES-containing vectors with 
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single-chain vectors, PBLs from donor 2 were transduced with TCR retroviruses after prior 
activation with plate-bound anti-CD3 and anti-CD28 antibodies. Expression of the TCRs 
was assessed by multimer staining. The TCR beta-IRES-TCR alpha configuration of the 
TCR chains which had previously led to high-level expression of the two TCRs in T cell 
lines was now less effective in primary donor 2 T cells (fig. 16). TCR beta-IRES-TCR 
alpha retroviruses transduced approximately 12% of primary T cells with TCR-LMP2a. 
However, no cells were transduced with the EBNA3a-specific TCR beta-IRES-TCR alpha 
construct. While the utilization of LMP2a single-chain TCR retrovirus did not increase the 
number of TCR-LMP2a-redirected T cells (only ~ 3% TCR expressing cells which was 
less effective than with the IRES-containing vector), the use of EBNA3a single-chain TCR 
retroviruses yielded a TCR-EBNA3a-specific expression of ~3% compared to the IRES 
vector. 
13.90 %
Donor 2 PBLs TCR LMP2a IRES
4.44 %
Donor 2 PBLs TCR LMP2a sc
1.56 %
Donor 2 TCR EBNA3a IRES
4.61 %
Donor 2 PBLs TCR EBNA3a sc
1.83 %
Donor 2 PBLs untransduced
FSC
1.43 %
Donor 2 PBLs untransduced
FSC
A
B
Fig. 16: TCR transduction into primary T cells. After activation with anti-CD3 and anti-CD28 
antibodies, primary T cells were transduced two times by spinoculation with TCR-encoding single-
chain (sc) retroviruses and IRES-containing (IRES) double-chain retroviruses. Tetramer staining 
after 72 hours demonstrated functional TCR expression after transduction with either TCR 
retrovirus. (A) Expression of the LMP2a-specific TCR was higher when IRES-containing 
retroviruses were used, whereas (B) expression of the EBNA3a-specific TCR was more efficient 
when single-chain constructs were used. 
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3.4.2.2 Cytolytic Function of TCRs after Transfer to Primary T cells 
Cytolytic function of TCR-transduced T cells was assessed in a standard five-hour 
51Cr release cytotoxicity assay. For each transduced TCR, one HLA-matched and one 
mismatched LCL were included in the assay as targets with and without external addition 
of the peptide of interest. Basic cytolytic activity towards antigen-presenting target cells 
was transferred into primary T cells by the introduction of TCR genes obtained from the 
parental clones (figure 17). Effector:target ratios were adjusted according to the number of 
multimer-positive T cells. Peptide-pulsed HLA-matched target cells were specifically lysed 
via both TCRs in an effector:target-ratio-dependent manner, whereas peptide-pulsed 
mismatched LCLs were not lysed. Moreover, TCR-LMP2a-transduced PBLs exhibited low 
lysis of HLA-matched, non-pulsed LCLs showing some recognition of endogenously 
processed antigen. The EBNA3a-specific TCR, in contrast, lysed an HLA-matched and 
peptide-pulsed LCL but failed to lyse the unpulsed LCL. Due to the lower percentage of 
multimer-positive cells (transduced with sc TCR constructs), a higher total number of 
T cells was used for TCR-EBNA3a-transduced T cells. Nevertheless, background lysis 
remained as low as for TCR-LMP2a-transduced T cells, demonstrating high specificity of 
the assay. Our results suggested that both CD8+ T cell-derived TCRs are of similar 
functionality with cytolytic capacity towards peptide-pulsed target cells. 
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Fig. 17: Antigen-specific cytotoxic activity of primary T cells after TCR transfer. Primary 
T cells from donor 2 transduced with retroviruses encoding LMP2a- and EBNA3a-specific TCRs 
were tested in a standard five-hour Cr-release assay. Effector:target ratios as indicated were 
calculated based on tetramer-positive cells. Mock-transduced (GFP) T cells did not lyse any targets. 
(A) TCR-LMP2a-transduced donor 2 T cells killed peptide-pulsed HLA-matched LCL targets 
(LCL4). Unpulsed HLA-matched LCL4 cells were only weakly recognized and killed. (B) TCR-
EBNA3a-transduced donor 2 T cells killed peptide-pulsed HLA-matched LCL3 targets, but failed 
to lyse unpulsed cells. In both experiments mismatched targets were not killed. Also, untransduced 
donor 2 T cells were unable to kill any LCLs. LCL3 is HLA-B8-positive and A2-negative, whereas 
LCL4 is HLA-B8-negative and A2-positive. 
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3.5 Modifications 
All isolated TCRs show antigen-specific function (Figure 14). Since the luciferase assay is 
only semi-quantitative, direct comparison between assays is not possible. Looking at the 
titrations, however, it seems as if TCR-LMP2a and TCR-EBNA2 most likely have better 
antigen sensitivity than TCR-EBNA3a. Optimization measures were now taken for all 
three TCRs (TCR-EBNA2-TVF, TCR-LMP2a-CLG; TCR-EBNA3a-FLR). In primary 
T cells the TCR retroviruses used (TCR-LMP2a-CLG and TCR-EBNA3a-FLR) were not 
as effective as desired when considering future clinical application. The TCRs are 
expressed at very low levels on primary cells and fail to effectively recognize EBV-
infected target cells without addition of peptide. The improvement measures we utilized, 
comprised vector optimization by replacement of the IRES site with a short peptide linker 
as well as codon modification. Optimized vectors encoding both CD8+ T cell-derived 
TCRs as well as the CD4+ T cell-derived TCR were generated. 
When we started to isolate TCRs and to construct retroviral vectors, the vector 
configuration containing a TCR beta-IRES-TCR alpha was, at that time, the optimal 
configuration. However, technological advances in the course of this project have exposed 
room for improvement. Based on the obtained data as well as on developments by us and 
others, novel strategies were chosen to improve the overall performance of the EBV-
specific TCRs. Using recombinant PCR, EBV-specific TCRs were cloned into TCR beta-
P2A-TCR alpha configuration, which to-date appears to be most effective [115]. 
Additionally, the TCR sequences themselves were optimized for expression in human 
cells. According to the company GeneArt, each nucleotide sequence was optimized for 
advantageous codon usage at the same time avoiding various sequences that might have 
caused problems in the original nucleotide sequence. Codon modification has been 
reported to be able to significantly improve TCR expression. 
These modifications tackle two critical parameters of successful TCR gene modification: 
Firstly, the vector itself by replacing the IRES site by the much more compact 2A linker in 
order to increase transduction efficiency as well as equimolar expression of both TCR 
chains. Secondly, the surface expression of the introduced TCR chains is improved by 
engineering of the nucleotide sequences for optimal codon usage and thus for optimal 
surface expression. 
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3.5.1 Optimized vs. non-Optimized TCR Retroviruses 
Non-optimized and optimized TCR retroviruses were used to transduce donor 3 PBLs. The 
TCR expression was measured by multimer staining or TCR Vbeta mAb staining. Due to 
interexperimental variation, direct comparison of old and optimized constructs was only 
possible within one individual experiment. For each experiment, virus titers were tested by 
transducing TCR-deficient J76 cells to ensure that equally potent supernatants were used. 
Function of TCR-redirected T cells was then determined using IFN-gamma ELISA assays. 
Different LCLs were tested as targets. LCLs that were well recognized by TCR-transduced 
T cells were then tested in chromium release cytotoxicity assays. 
3.5.1.1 EBV-specific TCR Expression in Primary T cells 
To test whether optimized TCR retroviruses would lead to better TCR surface expression, 
virus supernatants were produced for all three TCR specificities. For transduction of each 
TCR, the new retroviral vector (with 2A peptide linking codon-optimized TCR chains) as 
well as the corresponding non-optimized version of each vector was used (fig. 18). All 
supernatants were used to transduce TCR-deficient J76 cells to test the virus supernatant. 
Due to the lack of internal TCR chains in J76 cells, introduced TCR chains can assemble at 
the cell surface without competition. Thus, similarly potent viral supernatants should result 
in similar TCR surface expression on J76 cells as measured by anti CD3 antibodies. The 
same supernatants were used to transduce both J76 and primary T cells. Fig. 18 shows 
comparable transduction levels for each TCR after transduction into J76 cells, no matter 
which retrovirus was used. This indicates that similar-quality supernatants had been 
produced (figure 18A). However, when the same supernatants were used to transduce 
primary T cells from donor 3, the optimized retroviruses achieve markedly higher TCR 
expression both in mean fluorescence index (MFI) and total number of multimer- (or TCR 
Vbeta14 mAb, respectively) positive cells (figure 18B). An improvement is evident in all 
three cases, but is clearest in the comparison of the respective TCR-EBNA3a- and TCR-
EBNA2-encoding retroviruses. Optimized TCR-EBNA3a shows clear surface expression 
whereas the non-optimized vector had always failed to convincingly induce expression of 
the transferred TCR. For TCR-LMP2a and TCR-EBNA2 (non-codon-optimized TCR beta-
2A-TCR alpha) the non-optimized vectors were sufficient to modify the cells in a way that 
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the introduced TCR became detectable. TCR-EBNA3a surface expression, however, could 
not be transfered using the non-optimized vector. On the other hand, improvement was 
particularly prominent with this TCR when the optimized vectors were used. Whilst 
LMP2a- and EBNA2-specific TCRs showed a clear increase in the percentage of TCR-
positive cells (net increase of TCR-LMP2a: 0.75 % to 10.55 %; TCR-EBNA2: 9.46 % to 
15.26 %), TCR-EBNA3a became detectable at the cell surface after transduction with 
optimized TCR retrovirus (net increase: 0.00 % to 12.34 %). Also, the MFI increased by 
over threefold, whereas the MFI of the other two TCRs was about doubled. 
We took donor 3 T cells from this experiment that had received TCR-LMP2a using both 
optimized and non-optimized vectors to test, whether functional capacity is affected by the 
vector used. Hereby, the TCR-modified cells were cocultured with peptide-pulsed LCLs 
and IFN-gamma production tested by ELISA assay. As anticipated, the improved TCR 
expression with optimized constructs resulted in more efficient recognition of antigen-
positive target cells (fig. 19). However, the difference is marginal taking into account, that 
TCR expression was clearly higher when optimized vectors were used. 
Results 3.6 optimized vs. old TCRs
59
Fig. 18: Non-optimized vs. optimized TCR retroviruses. TCR-encoding retroviruses were 
modified by swapping of the IRES site for a 2A peptide linker. Furthermore, TCR genes were 
codon-optimized (co+). After transduction of PBLs from donor 3, expression was compared to non-
optimized constructs containing wildtype TCR genes and IRES sites. (A) TCR-LMP2a constructs 
were transduced into J76 cells as well as donor 3 PBLs. (B) TCR-EBNA3a were constructs 
transduced into J76 cells as well as donor 3 PBLs. In the case of TCR-EBNA2 (C), the optimized 
retrovirus was compared to a construct that contained the 2A linker, but whose TCR chains had not 
been codon-optimized. Virus supernatants were compared by transduction of TCR-deficient J76 
cells showing equally potent supernatants. The same supernatants were used to transduce PBMCs 
from donor 3, which resulted in a higher percentage of TCR-expressing cells as well as higher 
mean fluorescence indexes (MFI) of the improved constructs as compared to the old constructs. 
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Fig. 19: Optimized TCRs confer higher expression level and functional capacity. TCR-
transduced T cells (donor 3 as in Figure 18) were compared by ELISA for their ability to secrete 
IFN-gamma upon cocultivation with peptide-pulsed and HLA-matched LCLs. Although the viral 
supernatants with optimized (co+) and non-optimized (IRES) TCR retroviruses were equally potent 
in transducing TCR-deficient cell lines, TCR-transduced cells secreted more IFN-gamma when 
improved TCR retroviruses were used (green graphs). The peptide concentrations used for pulsing 
are noted in the figure, irrelevant control peptide was added at 10 µM. 
3.5.1.2 Target LCL Screening 
Our modifications to the vectors have resulted in more efficient expression of introduced 
EBV-specific TCRs in primary T cells. We were now to address whether the choice of the 
target LCL would play a role in the anti-EBV effect of our TCR-modified T cells. 
Here, primary T cells from donor 4 were transduced with the optimized versions of TCR-
LMP2a- and TCREBNA2-coding retroviruses. The “public” TCR-EBNA3a was not 
included in the screening experiments due to lack of novelty of the sequence. TCR 
modified donor 4 T cells were tested with different HLA-matched LCLs pulsed with 
titrated amounts of peptide in order to find the most suitable targets available to us. CD4+
T cell-derived TCR-EBNA2 co+ recognized three out of four tested LCLs without the need 
of additional peptide (figure 20A), whereas TCR-LMP2a co+ recognized only one out of 
four LCLs unless peptide was added (Fig. 20B). TCR-EBNA2-transduced T cells 
recognized EBV-infected LCLs GOELK, MDB1 and FSB1, but not LCL4 unless peptide 
was loaded. TCR-LMP2a recognized LCL JNB3 without addition of peptide but not LCLs 
1, 4 and STAB1. The corresponding transduction efficiencies are shown in figure 20C. 
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Fig. 20: LCL target screening. PBLs from donor 4 were transduced with optimized (co+) 
versions of (A) TCR-EBNA2 and (B) TCR-LMP2a. HLA-matched LCLs were pulsed with titrated 
amounts of antigenic peptide prior to cocultivation as depicted in the figure. Untransduced cells 
were used as control (open symbols). Pulsing with irrelevant control peptide was performed at a 
concentration of 10 µM. Antigen-specific activation was measured by IFN-gamma ELISA assay. 
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Fig. 20C: TCR expression after transduction of donor 4 PBLs. 
3.5.1.3 Function of EBV-specific TCR-modified T cells 
Optimized TCR vectors were used to transduce PBLs from donor 5. TCR-transduced 
T cells were then tested in a chromium release cytotoxicity assay against LCLs that were 
previously recognized in the ELISA screening experiment: GOELK and MDB1 as targets 
for TCR-EBNA2-transduced donor 5 PBLs as well as JNB3 and LCL1 for TCR-LMP2a-
transduced donor 5 PBLs. LCL1 was not recognized previously during screening; only 
JNB3 was recognized by TCR-LMP2a-transduced T cells. LCL1 would therefore serve as 
an HLA-matched control. 
All tested LCLs were killed by TCR-modified T cells transduced with the appropriate TCR 
when the correct peptide was prior pulsed onto the target cells. Killing of peptide-pulsed 
targets was more efficient with TCR-LMP2a-transduced TCRs, but was very clear with 
TCR-EBNA2-transduced T cells as well. However, when no peptide was added, only 
JNB3 and GOELK cells were killed by TCR-transduced T cells (fig. 21). Killing by TCR-
LMP2a-transduced T cells was relatively low as compared to the case of peptide-pulsed 
targets, but was still present at the lowest effector:target ratio tested. By contrast, killing by 
TCR-EBNA2-transduced T cells was better at high effector:target ratios, but dropped 
quickly with lower effector:target ratios. Neither LCL1 nor MDB1 were killed when 
unpulsed. Untransduced donor 5 T cells were unable to kill even peptide-loaded LCLs. In 
parallel, TCR-transduced donor 5 PBLs from the same transduction experiment (fig. 21C) 
were tested for their ability to secrete IFN-gamma upon antigen-specific activation (Fig. 
Results 3.6 optimized vs. old TCRs
63
22). In general, the results correlate to the observations from the cytotoxicity assay. JNB3 
and GOELK cells induce the strongest response in TCR-transduced cells, both with and 
without peptide. LCL1, as in the cytotoxicity assay, was not capable of activating TCR-
LMP2a-transduced cells, unless peptide is added. Notably, LCL MDB1, although able to 
induce IFN-gamma secretion (measured by ELISA) (fig. 22B), had not been effectively 
killed in the cytotoxicity assay (fig. 21B). 
Fig. 21: T cells transduced with optimized TCR retroviruses kill EBV+ target cells. Improved 
TCRs were tested for their cytolytic activity towards LCLs after transduction into PBLs from 
donor 5. In five-hour chromium release cytotoxicity assays effector:target ratios were calculated 
based on the number of tetramer- (TCR-LMP2a co+) and Vbeta14- (TCR-EBNA2 co+) positive 
cells, respectively. A) -EBNA2co+-transduced donor 5 PBMCs were cocultured with GOELK and 
MDB1 cells that were both recognized in ELISA. When the LCLs are loaded with antigenic 
peptide they are killed by the T cells. When no peptide was added only GOELK cells were lysed. 
B) For TCR-LMP2a co+-transduced T cells one LCL line that was well recognized in ELISA 
(JNB3) as well as one LCL that was not recognized in ELISA (LCL1) were tested. Both LCLs are 
HLA-A2-positive. Again only LCL JNB3 was detected and killed. LCL1 was only killed when the 
cells were prior loaded with antigenic peptide. 
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Fig. 21C: EBV-specific TCR expression in donor 5 PBLs after transduction with optimized TCR 
retroviruses. 
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Fig. 22: T cells transduced with optimized TCR retroviruses secrete IFN-gamma upon 
coculture with EBV+ LCLs. On the same day as the cytotoxicity assay shown in figure 21, donor 
5 PBLs transduced with optimized TCR retroviruses were also tested by IFN-gamma ELISA using 
the same LCLs as used in the cytotoxicity assay. A) TCR-LMP2a co+-transduced donor 5 T cells 
recognized unpulsed JNB3 cells whereas LCL1 cells were not recognized. B) TCR-LMP2 co+-
transduced donor 5 PBLs recognized unpulsed GOELK cells and also unpulsed MDB1 cells. 
MDB1 cells triggered even higher IFN-gamma secretion than GOELK cells. Untransduced T cells 
did not secrete IFN-gamma when cocultured with the LCLs. 
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4 Discussion 
Adoptive transfer of EBV-specific polyclonal T cell lines has been used successfully for 
prophylaxis and treatment of PTLD in patients after stem cell transplantation [70,116,117]. 
This treatment utilizes EBV-specific polyclonal T cell lines generated by stimulation of 
PBLs with EBV-transformed LCLs which express the same viral genes as the malignant 
cells of PTLD. In patients with advanced EBV+ Hodgkin´ s disease, adoptive T cell 
transfer experiments have shown that ex-vivo-expanded EBV-specific CTLs survived in 
the patients´ circulation for up to 12 months, did home to sites of disease and reduced the 
viral load and induced clinical remissions in only some cases [71]. However, the strategy is 
time-consuming and demands difficult generation of LCLs and corresponding T cells for 
each individual patient. As a result, some patients with very aggressive PTLD die of 
progressive disease even before the EBV-specific autologous cell lines become available. 
This limitation is possibly due to the fact that the bulk of each EBV-specific CTL line was 
directed against the immunodominant EBNA3 epitopes which were expressed by the 
stimulator LCL [70]. T cell specificity against disease-related antigens can be increased by 
generation of TCR-redirected T cells of defined antigen specificity. This allowed 
enhancing the EBV-specific immunity against both dominant and subdominant EBV 
antigens of each patient within a few of days in confinement of MHC restriction. 
4.1 T cell Clones 
Here, we report the successful generation of EBV-specific CD4+ T cell clones. One of the 
clones (0.3GG3EBNA2) and its characterization is shown in this work. Monoclonality was 
confirmed by direct sequencing of bulk RACE PCR products, after monospecificity had 
been seen by TCR Vbeta panel analysis and cytokine secretion assay. Furthermore, CD8+
T cell clones against one dominant EBV antigen expressed in PTLD and one subdominant 
EBV antigen also expressed in PTLD, but as well in EBV+ Hodgkin´ s disease and 
nasopharyngeal carcinoma were used in this work. These CD8+ clones had been previously 
generated in our lab. Tetramer staining confirmed monospecificity of our T cell clones 
which proved to be of high antigen-specific affinity. Analyzing the quality of T cell clones 
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is key for generation of functionally active TCR-redirected T cells as it was reported that 
no loss of TCR affinity occurs after gene transfer [118]. 
4.2 Role of CD4+ T cells 
Although the true significance of antigen-specific CD4+ T cells is not yet well established, 
numerous hints suggest the indispensable importance of CD4+ T cells. A recent study has 
pointed out the importance of CD4+ cells in the treatment of a melanoma patient [119]. In 
that report, infusion of a clonal CD4+ population led to complete regression of a tumor. 
T helper cells are sometimes even considered to be more effective than other T cell 
phenotypes in fighting cancer [120]. Also, we had observed low absolute CD4+ T cell 
counts to be associated with an elevated EBV load in solid organ recipients with PTLD 
[121]. It appeared as if the frequency and function of circulating EBV-specific CD8+
T cells are dependent on absolute CD4+ T cell numbers. However, it remains to be verified 
whether low absolute CD4+ T cell counts actually present a risk factor for the development 
of PTLD. 
Furthermore, in a multi-center phase-II study with PTLD patients, a significant trend 
towards better responses with a higher percentage of CD4+ cells being co-infused with 
polyclonal anti-EBV CTL lines was observed [33]. In that study, polyclonal T cell lines 
containing CD4+ and CD8+ T cells were used, with the percentage of CD3/CD4+ cells 
ranging from less than 1 to 60 %. When the administered cell preparations contained less 
than 1 % of CD4+ T cells 1 to 4.9 % of patients showed a response, whereas the response 
rate was 92 % when the received T cells contained more than 5 % of CD4+ cells. The 
beneficial effect of CD4+ cells was striking and the positive trend was maintained after six 
months (18 % and 83 % vs. 4.9 % and 92 %). 
To-date, our knowledge about the contributions of CD8+ and CD4+ T cells in adoptive 
T cell therapy is far from complete. Both, cytotoxic T cells as well as helper T cells that 
secrete high levels of cytokines are required for effective cellular immunity. Class II-
restricted T cell receptors are known to mediate cytotoxic as well as helper activity 
depending on whether they are transferred to CD4+ or CD8+ cells. MHC class I-restricted 
T helper cells, created by TCR transfer into CD4+ cells, produced cytokines, expressed 
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CD40L, proliferated and induced DC maturation in an antigen-specific manner [122]. 
Using MHC class II-/- mice the same group showed that such class I-modified CD4+ T cells 
can provide antigen-specific help to CD8+ T cells in vivo. However, antigen-specific 
responsiveness of CD4+ T cells that had prior received class I-restricted ovalbumin- or 
influenza-specific TCR was strongly dependent on the CD8 alpha/beta coreceptor. 
Therefore it is crucial to take class II-derived TCRs into account and not just focus on 
class I-derived TCRs. Nevertheless, our current understanding of the in-vivo interplay of 
CD4+ and CD8+ cells, as well as their functional dedications, remains quite dim. In this 
work we describe the generation of an EBV-specific CD4+ T cell clone and the isolation 
and transfer of its TCR. TCR from such cells have not yet been described and will 
hopefully help in improving the understanding of anti-EBV immune intervention. Being 
able to generate class I- as well as class II-restricted TCRs for transfer into CD4+ or CD8+
T cell populations might assist in improving the overall efficacy of the therapeutic 
approach. 
4.3 The Use of Peptide-Pulsed DCs as APCs 
It was shown that peptide-pulsed DCs can be superior to LCLs in generating EBV-specific 
T cells for any desired epitope including subdominant ones such as LMP2 [15]. Here, 
Subklewe et al. showed that DCs can be 10-fold more efficient than LCLs in expanding 
EBV-specific T cells and were also more efficient at complex formation with T cells. 
Additionally, DCs were better at inducing T cell responses against the rare subdominant 
epitopes. Indeed, we have successfully applied this approach to generate T cell clones 
specific for epitopes from LMP2a, EBNA3a and EBNA2. However, it is sometimes argued 
that using peptide-pulsed APC the vast abundance of antigenic peptide leads to elimination 
of the most potent cells resulting in the enrichment of low-affinity T cells only. Critics 
argue that such low-affinity T cells would only lead to isolation of TCRs which are 
immunologically less relevant and would thus lead to failure due to low expression and 
functional capability. Although this criticism might be legitimate, confirmatory 
experimental data is lacking. Our approach, on the other hand, appears to be justified by 
the fact that we have isolated TCR-EBNA3a and found it to resemble the “public” TCR 
commonly selected in the T cell response to the corresponding EBV epitope [123,124]. 
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Such “public” TCRs are believed to be particularly suitable to in-vivo recognize their 
corresponding antigen in a very efficient way. Thus, the concern about the DC approach 
being prone to failure is, in this case, unsubstantiated. Nonetheless, mRNA transfection 
into DCs would be an attractive alternative to the external addition of peptides since 
intracellular expression and antigen processing then better resembles the in-vivo situation. 
Notably, gamma delta T cells have been suggested as another source of antigen-presenting 
cells [125]. It  was shown that gamma delta T cells were similarly potent as DCs to 
stimulate functionally competent EBV-specific CTLs [126]. Such autologous “T-APCs” 
can be induced ex-vivo by pharmacologically relevant doses of biphosphonates such as 
zoledronate. However, limitations still apply and LMP2-specific T cells could not yet be 
generated with this approach (personal communication with S. Landmeier). Although 
further characterization is required, “T-APC” might represent a welcome source of 
antigen-presenting cells for both in-vivo and ex-vivo stimulation. 
4.4 EBV-specific TCRs 
There have been several reports describing the identification of TCRs from EBV-specific 
T cell clones. Two reports have previously described the transfer of EBV-specific TCRs 
into recipient T cells to confer anti-EBV reactivity [46,47]. These endeavors, however, 
were hindered by poor TCR expression and low effectiveness. As a result, TCR-modified 
T cells that recognize EBV epitopes have been stagnating on their way to clinical 
application. Yet we still believed that redirected T cells remain an attractive option for 
immunotherapy of EBV-associated disease. With TCR technology undergoing constant 
development [127], we were hoping to overcome the problems that had been encountered 
in the past. In this work, the isolation of three TCRs and the generation of corresponding 
viral vectors are described. They recognize epitopes derived from LMP2a, EBNA3a and 
EBNA2. TCR-LMP2a targets the same epitope as TCRs described earlier by others 
[46,47], but is composed of novel TCR chains that might promote improved antigen 
recognition and killing. LMP2 is expressed in PTLD as well as in EBV+ HD and NPC. 
Also, EBV+ Hodgkin cells have a functional class I antigen presentation machinery and 
are, therefore, potentially suitable for T cell therapy [69]. TCR-EBNA3a corresponds to a 
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TCR alpha and beta chain combination frequently found in different HLA-B8+ individuals 
in which this TCR combination tends to dominate the anti-EBV response. The fact that we 
identified this public TCR with DC priming, confirms the concept of our approach to 
enrich EBV-specific T cells from the periphery and to molecularly clone the correct TCR. 
CD4+ T cell-derived TCR-EBNA2 is a novel TCR targeted against an HLA class II 
promiscuous epitope [112]. It has been shown that targeting this epitope can inhibit EBV-
driven B cell proliferation associated with PTLD and due to its restriction to many class II 
alleles might be applicable to a major fraction of the population [112]. Furthermore, EBV-
specific TCRs from a CD4+ T cell clone have not yet been described. The TCR described 
in this work might, therefore, contribute to a better understanding of the role of CD4+
T cell-derived TCRs, especially in the context of EBV. 
4.5  Recognition of Different LCL Targets 
Although anti-EBV activity could be transferred with EBV-specific TCRs, recognition of 
LCL lines was inconsistent. Whilst some LCLs are effectively recognized and killed by 
TCR-engineered T cells, others failed to activate the T cells via their TCRs. They required 
external addition of peptide in order to be recognized. It is a frequent observation that CTL 
lines and clones fail to lyse EBV-positive LCLs. Hill et al. described that CTL are often 
unable to lyse even autologous LCLs against which they had been initially expanded [128]. 
Addition of peptide or superinfection with recombinant vaccinia virus containing 
appropriate EBV protein was required to render the LCLs capable of inducing cytotoxic 
activity in CTLs. The underlying mechanisms are not quite understood. According to Hill 
et al., the lack of cytotoxic activity towards the LCLs could neither be accounted to a 
certain epitope nor to protein expression of the antigen, nor to lack of availability of MHC 
molecules or impaired susceptibility of the LCLs to T cell-mediated lysis. It was concluded 
that the avidity of interaction between LCL and CTL was too low to trigger effector 
function in CTL and that alteration of one determinant of the interaction (either epitope 
density or TCR affinity / expression) could lead to antigen-specific lysis of LCLs. Here, it 
seems as if in-vitro the epitope density on LCL lines which is required to specifically 
stimulate and expand T cells is lower than that needed to trigger cytotoxic effector function 
in T cells. However, it is unknown whether these CTLs would be able to lyse EBV-
infected cells in-vivo. Since immune control of EBV infection is obviously effective in 
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healthy individuals, this might well be the case although difficult to demonstrate in-vitro. 
One possible reason for such poor antigen presentation is the EBV gene product BNLF2a, 
which has been reported to block TAP-catalyzed peptide translocation from the cytoplasm 
to the endoplasmic reticulum (reviewed in [129]). As a result, EBV-infected cells’ 
susceptibility to CD8+ EBV-specific T cell recognition diminishes as they simultaneously 
exhibit decreasing TAP activity and surface MHC expression. Also, an evasive strategy of 
EBV to stealth itself from recognition via CD4+ T cells has been suggested. A soluble form 
of gp42, a product of the EBV BZFL2 gene, can be secreted to bind MHC class II 
molecules preventing interactions with TCR complexes on CD4+ T cells [130]. MHC class 
II (HLA-DR) itself serves as a co-receptor for EBV infection [131]. Generally, during its 
co-evolution with its human host, EBV has developed diverse strategies to avoid 
elimination by the host immune system. Although EBV infection can be controlled in 
immunocompetent hosts, the virus cannot be cleared completely.  
Furthermore, it is noteworthy that we utilized an IFN-gamma ELISA to screen for suitable 
LCLs that could trigger TCR-transduced T cells in an antigen-specific way. However, the 
use of IFN-gamma ELISAs for screening has some limitations. IFN-gamma secretion does 
not always correlate with cytotoxic activity of the same T cells when stimulated with a 
certain LCL line. This is also obvious in the cytotoxicity assay with TCR-EBNA2-
transduced donor 5 PBLs, when MDB1 cells were not lysed by the T cells, but where able 
to induce IFN-gamma secretion. 
4.6 Non-Optimized TCRs Compared to Published EBV-specific TCRs  
Different methods of TCR transfer resulting in variable transgene expression have been 
reported [46,132]. To achieve stable and high-level transgene expression, we initially 
chose the retroviral vector MP71 [107] for TCR transduction where the TCR alpha and 
beta chain genes were linked by an IRES element in the order TCR beta-IRES-TCR alpha. 
We have previously applied this gene order to functionally express other human [133] as 
well as murine TCRs [45]. Tetramer staining showed correct TCR complex formation on 
the cell surface by specific MHC-peptide binding. As a common finding, TCR transgene 
expression was not as efficient in PBLs as it was in cell lines. Whilst expression of TCR-
LMP2a was higher when the IRES-linker double-chain TCR construct was used, TCR-
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EBNA3a expression was only detectable when the PBLs were transduced with single-
chain TCR retroviruses. This indicates TCR chain-dependent appropriateness of each 
construct. Also, this finding complies with data from Prof. Uckert’s lab showing variable 
effectiveness of different constructs for TCR transfer [115]. However, the governing 
mechanisms are not yet quite understood. Using nucleofection and retroviral transduction 
to redirect donor PBLs to EBV antigens has, so far, only led to very low expression levels 
of less than 2% [46]. Moreover, nucleofection does not allow stable transgene expression 
over an extended period of time. We show that introduction of EBV-specific TCRs into 
donor PBLs using a retroviral vector confers functional capacity to transduced PBLs. 
Importantly, in our experiments sufficient TCR expression and function is achieved 
without any additional selection or enrichment steps. High-affinity TCRs have been 
suggested to be the key determinant for high-avidity T cells [118,134]. Our experiments 
demonstrated that TCR-transduced PBLs show high TCR affinity upon LMP2a peptide 
stimulation as detected by IFN-gamma ELISPOT which is similar to original TCR affinity 
of T cell clones. This is in agreement with others which have shown that transferred TCR 
maintained the avidity of the original T cell clone [118]. 
When using constructs with TCR beta-IRES-TCR alpha configuration, antigen-specific 
killing of peptide-pulsed LCL targets was measured at 65 – 72 % for both CD8+ T cell-
derived TCRs, which is markedly higher than in previous reports at the depicted E:T ratio 
[46]. However, differing experimental procedures make a direct comparison difficult. 
Unpulsed HLA-matched LCLs were also lysed by TCR-LMP2a-transduced T cells even 
though less effectively than pulsed LCLs, but at levels equal to recent reports [46]. T cells 
that had received TCR-EBNA3a failed to lyse unpulsed HLA-matched LCLs. This is very 
likely due to a mutation harbored by the B95-8 EBV strain used to generate this LCL. It 
has been reported that processing and presentation of the mutated EBNA3a-FLR epitope 
results in ten-fold decreased binding of specific TCRs [110]. In summary, we achieved 
functional EBV-specific TCR expression at levels higher than previously reported. 
However, the functional capacity of T cells after introduction of unmodified IRES-
containing TCR vectors was not markedly superior to already published data. 
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4.7 Vector Optimizations 
Still not satisfied with our results, we sought to improve expression and function of our 
transferred TCRs. Finally, codon-optimized vectors were used which, in addition, had their 
IRES sites replaced by a 2A linker. When transferred into a recipient T cell, introduced 
TCRs face competition by the already present endogenous TCR. A “weak” TCR will very 
likely not achieve sufficient expression levels at the cell surface whereas a “strong” TCR 
can almost completely suppress expression of the endogenous TCR [45]. Competition is 
believed to occur during complex formation with CD3 components that might be a limiting 
factor. The idea is backed up by observations of one TCR, although present in equal 
amounts as the other, being completely withheld inside the cell [135]. Other factors that 
might aggravate correct TCR formation at the surface are preferential mispairing with 
endogenous TCR chains or disadvantageous codon usage. Still, the molecular and 
mechanistic prerequisites that render particular TCR “weaker” or “stronger” as compared 
to another are unresolved. 
The modifications to the vector utilized in this work comprise codon optimization and 
introduction of a 2A linker instead of the IRES site. Codon optimization of TCRs has first 
been reported effective in improving expression by Scholten et al. [48] and, since then, has 
been confirmed to benefit TCR expression in many cases. In the process of codon 
optimization, advantageous codons are chosen with regard to the availability of the 
corresponding tRNA. At the same time rare codons, as well as RNA instability motifs and 
undesired splice sites etc. are eliminated from the nucleic acid sequence. By increasing 
desired TCR gene expression competition is skewed in favor of the introduced TCR. 
Replacing the IRES site with the much smaller 2A linker [49] is another way of increasing 
TCR expression as a result of improved efficiency in transfection and transduction. 
Furthermore, the adoption of the linker, in theory, provides equimolar expression of both 
introduced TCR chains; alpha and beta chain genes can be translated by the same ribosome 
which receives a skip signal by the linker, thus releasing the beta chain before translating 
the downstream alpha gene. In our experiments, the modifications consistently led to 
higher percentages of T cells which expressed the introduced TCR as well as higher mean 
fluorescence values when directly compared to the vectors with non-optimized sequences 
and an IRES site. 
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Codon optimization and the replacement of the IRES site by a 2A peptide linker are 
primarily aimed at better expression levels of the introduced TCR genes. Another strategy 
to increase functional avidity is the defined removal of N-glycosylation sites within the 
TCR constant region in order to alter flexibility, movement and interaction of TCRs at the 
cell surface which has resulted in increased antigen-specific functional capacity [136]. 
Other modifications aim at an improved pairing of both introduced TCR chains avoiding 
“mismatched” TCRs where one introduced TCR chain forms a heterodimer with an 
endogenous TCR chain. Such measures comprise the introduction of an additional 
disulfide bond [137,138] or the construction of chimeric receptors with a murine constant 
region [139,140]. Furthermore, TCRs incorporating human CD3-zeta showed very 
selective pairing of the introduced modified TCR chains [141]. Also, a “reciprocal 
mutation” was introduced as another means of favoring matched pairing of introduced 
TCR chains [142]. These measures could promote preferred TCR pairing and could reduce 
the risk of autoreactivity by hybrid TCRs. However, these modifications require alterations 
to the amino acid sequence of the TCR and are, therefore, criticized for potentially being 
immunogenic as well as for other unpredictable effects e. g. on the vitality and function of 
such modified cells. In the past, engineering of TCR chains have let to numerous strategies 
to improve functional avidity and preferential pairing. Yet, it remains to be elucidated 
whether the findings apply in general or whether they are dependent on the particular TCR 
used. 
4.8 TCR Affinity 
Before optimizing a TCR it is advisable to first select the best TCR to start with. TCRs 
with high affinity are currently considered the best basis for successful modification of 
T cells. However, T cells with high-affinity TCRs against self antigens are usually 
eliminated in the thymus during development [143]. This selection can potentially avoid 
autoreactivity. Tumor-associated antigens, however, frequently happen to be self antigens, 
too. Therefore, it is believed that T cells surviving thymic selection are usually equipped 
with low-affinity TCRs that would not suffice when faced with tumor-associated antigens. 
Several approaches have been developed to obtain higher-affinity TCRs. For example, 
high-affinity TCR-like proteins can be isolated by biochemical engineering tools such as 
phage display [144,145]. Another method utilizes an HLA-mismatch setting where a 
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desired HLA molecule is transferred into HLA-mismatch recipient cells to raise allo-
restricted T cells [146,147]. To achieve this, DC are electroporated with antigen-coding 
RNA alongside allo HLA-coding RNA to make the DC stimulate allorestricted T cells 
after antigen processing. Also, human TCR-transgenic mice are being developed that, 
instead of the murine TCR loci, carry the human TCR alpha and beta loci as well as a 
human HLA gene. Upon immunization with a human antigen, these mice install a cellular 
response with T cells expressing human TCRs. With the antigen being foreign to the mice, 
this might be an elegant way to isolate high-affinity TCRs. Further experiments are 
required to elucidate the optimal degree of TCR affinity. If the affinity of a TCR is too 
high, unwanted side effects can occur. Such side effects could be increased on-site toxicity 
e. g. observed as skin rashes in a recent clinical study (conducted by the Rosenberg group) 
with high-affinity melanoma-specific TCR-modified T cells [44]. 
Generally, the unavailability of high-affinity TCRs due to thymic selection is mainly a 
problem of self antigens. EBV and other viral antigens that are foreign to the human host 
should be able to elicit sufficiently strong T cell responses. Also, one of the TCRs that we 
isolated (TCR-EBNA3a) corresponds to the “public TCR” which is frequently selected in-
vivo. Such public TCRs are observed to dominate the response to the same antigenic 
epitope in multiple patients. Although explanations for public T cell responses and the 
underlying mechanisms still lack convincing backup by experimental data [148], some 
studies have pointed towards an antigen-specific advantage by “enhanced fit” or higher 
TCR affinity [149,150]. 
4.9 Potential Risks with TCR-modified T cells 
Formation of mismatched T cell receptors consisting of one introduced and one 
endogenous TCR chain has been shown [45,151]. It has also been reported that dominant 
TCR chains can suppress inferior TCR chains by preventing them from complex formation 
with CD3 at the surface [45]. However, coexpression of two TCRs resulting in dual-
specific T cells is also possible [45,152]. In this work, the presence of the endogenous TCR 
alpha chain in Jurkat/MA cells does not inhibit functional formation of LMP2a-, EBNA2- 
and EBNA3a-specific TCRs consisting of both introduced chains indicating the relative 
dominance of the introduced alpha chains. This is obvious from equal expression levels in 
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TCR alpha/beta double-deficient Jurkat76 cells and TCR beta chain-deficient Jurkat/MA 
cells. Dominance and correct formation of introduced TCR chains are very important 
factors since dual-specific T cells as well as hybrid TCRs remain an unpredictable risk 
factor. Autoimmunity can result from formation of mismatched TCRs with unknown 
specificity as well as from activation of endogenous, otherwise quiescent, TCRs upon 
antigen ligation of the introduced TCR. The second study with TCR-modified T cells 
recognizing melanoma antigens has recently demonstrated such autoimmune reactions 
when, after transfer of TCR-modified T cells, patients exhibited destruction of normal 
melanocytes in the skin, eye and ear, and sometimes required local steroid treatment [44]. 
Another hazard when using retroviral vectors is that of insertional mutagenesis. Integration 
of the TCR retroviruses can occur in disadvantageous locations and promote malignant 
transformation by activation of proto-oncogenes or by silencing of tumor suppressor genes. 
Different safeguard strategies have been designed to abort cellular therapy in case of 
severe autoimmune disease or malignant transformation. Among others, such strategies 
comprise suicide genes [153], apoptosis-inducing fusion genes [154] or depleting 
antibodies [155,156]. Alternatively, recent focus has been laid on lentiviral vectors for 
TCR gene transfer [127]. Lentiviral vectors are self-inactivating (SIN) which reduces the 
risk of unwanted effects of insertional mutagenesis. (SIN retroviral vectors have also been 
constructed, but have not yet been applied in a clinical setting [157].) Also, lentivectors 
have a different target site preference than retroviral vectors which, other than lentiviral 
vectors, tend to integrate in close proximity to transcription factor binding sites, thus, in 
theory, bearing a higher risk for human gene therapy applications [158]. In addition to 
other potential advantages (higher transgene capacity, ability to infect non-triggered 
T cells, even cell-specifically targeted delivery by using modified and cytoplasmic tail-
truncated hemagglutinin envelope glycoproteins of measles virus has been demonstrated 
[159]), the safety factor might give lentiviral vectors an edge over retroviral vectors in the 
future. Besides the safety issue, the ability to transduce resting T cells is particularly 
appealing when considering lentiviral vectors for T cell based gene therapy [160]. 
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4.10  Clinical Setting 
Our study supports the development of immunotherapeutic strategies for EBV-associated 
diseases using TCR-redirected T cells. We propose the use of TCR-LMP2a- and TCR-
EBNA3a-redirected T cell lines for adoptive transfer in HLA-B8+ or HLA-A2+ organ or 
bone marrow (peripheral blood stem cell transplantation) transplant recipients with PTLD. 
Through the HLA-restriction this could be an option for 20% (HLA-B8) to 50% (HLA-A2) 
of the Caucasian patient population [161]. Furthermore, the use of the promiscuous class-
II-restricted TCR-EBNA2 can further enlarge the cohort of treatable patients. EBV sero-
negative status is an established risk factor for the development of PTLD after organ or 
marrow transplantation. Our method of TCR transfer will also allow the use of adoptive 
T cell therapy in this high-risk patient cohort, as priming of EBV-specific immunity in 
EBV sero-negative donors would no longer be necessary. In the immunocompetent host, 
EBV-associated malignancies including Hodgkin´s disease and nasopharyngeal carcinoma, 
express a limited array of EBV genes [46,162]. To improve effectiveness of adoptive T cell 
transfer in this patient cohort, TCR-redirected T cells will allow us to increase specificity 
against subdominant EBV antigens, like LMP2a. This approach is supported by 
immunohistochemical studies on Hodgkin´ s disease biopsies and in-vitro analysis of 
Hodgkin-Reed-Sternberg cell lines which strongly suggest that these cells are able to 
present endogenously synthesized EBV proteins. Also, the use of TCR-redirected T cells 
will enable us to monitor the fate of adoptively transferred T cells in-vivo. Clinical studies 
are needed to test the potential of TCR-redirected T cells for adoptive T cell therapy in the 
different EBV-associated malignancies. 
4.11 Conclusion and Outlook 
Starting in the late 1980s, TCR gene transfer has undergone intensive investigation and 
constant development during the last decade. A first clinical trial in melanoma patients has 
provided proof of concept for the safety and feasibility of TCR-modified T cells for 
adoptive cancer therapy [42] (although the second study, which used high-affinity TCRs, 
has also shown that severe side effects can occur [44]). Nevertheless, the results of the first 
study were not very positive with a response rate of only 2 out of 17 patients. The 
expression of the introduced TCR in this trial was low and varied markedly between 
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patients. Also, the clinical effectiveness was lower than that previously achieved by 
adoptively transferred unmodified T cells in different disease settings [29]. 
In order to improve the effectiveness of the TCR gene transfer approach several 
optimization strategies are pursued: vector modifications to improve expression of the 
transferred TCR, how to identify the best TCRs, the particular cells that are used, which 
conditions they require for best results as well as safeguard mechanisms. Various 
modifications to the original TCR sequences have been applied. These modifications aim 
at improved expression (codon optimization, 2A linker) or at improved preferential pairing 
(disulfide bond, murinization, etc.). As a result, the problem of very low transgenic TCR 
expression in recipient cells that was often encountered in the past is essentially solved. 
TCR affinity is believed to heavily influence the effectiveness of TCR-modified T cells. 
Several technological approaches are under development which will, hopefully, allow 
isolation of high-affinity TCRs in the future. However, one has to be cautious when 
choosing the degree of TCR affinity, since affinities that are too high are very likely going 
to cause unwanted side effects. 
On a cellular basis, it is desirable to transfer highly potent cells that are characterized by 
effectiveness, persistence, proliferative capacity and safety. Extended in-vitro manipulation 
of T cells seems to render them relatively ineffective since, once transferred after in-vitro
culture, they appear somewhat exhausted [127,163]. Recent considerations have also 
focused on introducing TCR genes into hematopoietic stem cells instead of T cells to 
provide long-term availability of antigen-specific cells and at the same time avoiding TCR 
competition and hybrid TCR formation. Risks and benefits of this approach are being 
assessed to date. Insertional mutagenesis in the case of stem cell modification, as well as in 
general, remains to be of particularly great concern. The occurrence of malignant T cell 
proliferation in X-SCID patients who had received gene therapy with gene modified stem 
cells, has demonstrated that such a threat is real and safety must always be considered 
[164]. 
Further engineering of the TCRs as well as addition of further genes to antigen-specific 
cells have also been assessed. In the past, fusing EBV antigen-specific TCRs to the 
signaling domains of CD28 [100] or equipping EBV-specific CTLs with dominant 
negative TGF-beta receptor II (DNRII) [165] has shown positive effects. The CD28 
signaling domain was designed to enhance the intracellular signaling after antigen 
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engagement of the TCR whereas introduction of DNRII can make T cells resistant to the 
negative effects of TGF beta secreted by tumor cells. 
The research field of TCR gene transfer for adoptive therapy has been picking up 
momentum and will hopefully improve our knowledge of tumor immunology and 
significantly add to our arsenal of anti-tumor and anti-viral therapeutics. 
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6 Abbreviations 
ADCC antibody-dependent cell-mediated cytotoxicity 
AIDS  aquired immuno deficiency syndrome 
APC antigen-presenting cell 
ATCC American tissue and cell collection 
BL Burkitt’s lymphoma 
BLAST basic logic alignment search tool 
BSA bovine serum albumine 
CD cluster of differentiation 
CDC complement-dependent cytotoxicity 
cDNA complementary DNA 
CHOP 
cyclophosphamide/doxorubicin 
hydrochloride/oncovin/prednisolon chemotherapy 
CIAP  calf intestine alkaline phosphatase 
CIP calf intestine phosphatase 
CDC complement-dependent cytotoxicity 
co+ codon-optimized 
CTL cytotoxic T lymphocyte 
Ctrl control 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP Deoxynucleosidetriphosphate 
DSMZ German resource center for biological material
EBNA Epstein-Barr nuclear antigen 
EBV Epstein-Barr virus 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
FACS  fluorescence-activated cell sorting 
FCS  fetal calf serum 
FITC  fluoresceine isothiocyanate 
Fig. figure 
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GM-CSF granulocyte macrophage colony-stimulatory factor 
HD Hodgkin’s Disease 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HRSC Hodgkin-Reed-Steinberg cell 
IM infectious mononucleosis 
IMGT international immunogenetics information system 
IFN interferon 
IL interleukin 
IRES internal ribosomal entry site 
LB – Medium  lysogeny broth medium 
LCL  lymphoblastoid cell line 
LMP latent membrane protein 
LTR long terminal repeat 
mAb monoclonal antibody 
MACS magnetic cell separation 
MAGE 1 / 2 melanoma antigen 1 / 2 
MFI mean fluorescence index 
MHC major histocompatibility complex 
mRNA messenger RNA 
NCBI national center for biotechnology information 
NPC nasopharyngeal carcinoma 
OD optical density 
PBL peripheral blood lymphocyte 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PE phycoerythrine 
PGE2 prostaglandin E2 
PHA-L phytohemagglutinin 
P/I/S PMA/Ionomycine/SEB 
PMA phorbol-12-myristat-13-acetat 
Abbreviations 
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PRE  post-transcriptional regulatory element 
PI propidium iodide 
PTLD post-transplantation lymphoproliferative disorder 
RACE rapid amplification of cDNA ends 
RLU relative light units 
RNA ribonucleic acid 
RT reverse transcription / transcriptase 
SEB Staphylococcus enterotoxin B 
S.O.C – Medium modified super optimal broth Medium (glucose added) 
TAA tumor-associated antigen 
Tab. table 
TAE  tris acetate EDTA buffer 
TAP  tobacco acid pyrophosphatase 
TAP transporter associated with antigen processing 
TNF tumor necrosis factor 
Tris tris(hydroxymethyl) – aminomethane 
TCR T cell receptor 
TSA tumor-specific antigen 
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